US20050143715A1 - Device for controlled reservoir opening with reinforced reservoir caps - Google Patents

Device for controlled reservoir opening with reinforced reservoir caps Download PDF

Info

Publication number
US20050143715A1
US20050143715A1 US10937616 US93761604A US2005143715A1 US 20050143715 A1 US20050143715 A1 US 20050143715A1 US 10937616 US10937616 US 10937616 US 93761604 A US93761604 A US 93761604A US 2005143715 A1 US2005143715 A1 US 2005143715A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
reservoir
device
reservoirs
contents
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10937616
Inventor
Michael Cima
John Santini
Stephen Herman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0097Micromachined devices; Microelectromechanical systems [MEMS]; Devices obtained by lithographic treatment of silicon; Devices comprising chips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T137/00Fluid handling
    • Y10T137/8158With indicator, register, recorder, alarm or inspection means
    • Y10T137/8225Position or extent of motion indicator
    • Y10T137/8242Electrical

Abstract

Device are provided for the controlled release or exposure of molecules or secondary devices comprising a substrate; a plurality of reservoirs located in the substrate; reservoir contents comprising molecules, a secondary device, or both, isolated inside the reservoirs; reservoir caps positioned on the reservoirs over the reservoir contents, wherein the reservoir caps (which can comprise a metal film) are mechanically reinforced with a second material deposited and patterned on the surface of the metal film inside the reservoir or on the surface of the metal film outside the reservoir or on both of said surfaces; and control circuitry and a power source for disintegrating the reservoir caps to initiate exposure or release of the reservoir contents in selected reservoirs.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This is a continuation of U.S. application Ser. No. 10/159,550, filed May 31, 2002, now U.S. Pat. No. ______. U.S. application Ser. No. 10/159,550 claims benefit of U.S. Provisional Application No. 60/294,818, filed May 31, 2001. All of these applications are incorporated herein by reference in their entirety.
  • BACKGROUND OF THE INVENTION
  • This invention relates to miniaturized devices for the controlled exposure or release of molecules such as drugs and/or secondary devices such as sensors.
  • U.S. Pat. No. 5,797,898 to Santini Jr., et al. discloses microchip delivery devices which have a plurality, typically hundreds to thousands, of tiny reservoirs in which each reservoir has a reservoir cap positioned on the reservoir over the molecules, so that the chemical molecules (e.g., drugs) are released from the device by diffusion through or upon disintegration of the reservoir caps. The reservoirs may have caps made of a material that degrades at a known rate or that has a known permeability (passive release), or the caps may include a conductive material capable of dissolving or becoming permeable upon application of an electrical potential (active release).
  • In the active release devices, the reservoir cap can be a thin metal film. Application of an electric potential causes the metal film to oxidize and disintegrate, exposing the contents of the reservoir to the environment at the site of the microchip device. It would be advantageous to enhance this oxidation and disintegration across the surface of the metal film, in order to achieve consistent and reliable exposure of the molecules and secondary devices contained in the reservoirs. It would be particularly desirable, for example, to provide microchip devices that provide highly reliable and precise exposure of drug molecules located in reservoirs in the microchip delivery devices to the environment in which the microchip device is implanted. More generally, it would be desirable to provide devices and methods to enhance the opening of reservoir caps in microchip devices for the controlled exposure or release of reservoir contents.
  • SUMMARY OF THE INVENTION
  • Microchip devices and methods of manufacture thereof are provided to increase the uniformity and reliability of active exposure and release of microchip reservoir contents. In one embodiment, the microchip device for the controlled release or exposure of molecules or secondary devices comprises: (1) a substrate having a plurality of reservoirs; (2) reservoir contents comprising molecules, a secondary device, or both, located in the reservoirs; (3) reservoir caps positioned on the reservoirs over the reservoir contents; (4) electrical activation means for disintegrating the reservoir cap to initiate exposure or release of the reservoir contents in selected reservoirs; and (5) a current distribution means, a stress induction means, or both, operably engaged with or integrated into the reservoir cap, to enhance reservoir cap disintegration.
  • The device can further include a cathode, wherein the reservoir caps each comprise a thin metal film which is an anode, the electrical activation means comprises a means for applying an electric potential between the cathode and the anode effective to cause the reservoir cap disintegration to occur electrochemically. The device can, alternatively or in addition, further include at least one resistor operably adjacent the reservoir caps, wherein the electrical activation means comprises a means for applying an electric current through the resistor effective to cause the reservoir cap disintegration to occur thermally.
  • In one embodiment, the current distribution means can comprise a current distribution network mounted on or integrated into the reservoir cap. In another embodiment, the current distribution means can include an electrochemically plated metal layer on the outer surface of the reservoir cap, wherein the metal layer has increased surface roughness relative to the outer surface of the reservoir cap. The stress induction means can comprise a pre-stressed structure attached to or integrated into the reservoir cap, the pre-stressed structure providing a force substantially perpendicular to the surface of the reservoir cap. In one embodiment, the pre-stressed structure comprises a bilayer cantilever beam. In other embodiments, the pre-stressed structure has a spring, coil, or cross structure.
  • Methods of fabricating and using these devices are also provided.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 a is perspective diagram of one embodiment of a microchip chemical delivery device, in partial cross-section showing chemical filled reservoirs and membrane reservoir caps, and FIG. 1 b shows the shape of the reservoir.
  • FIG. 2 is a graph showing cyclic voltammetry data for gold in 0.145 M NaCl solution (pH=5.5-6.0), wherein the current peak at 1.0-1.2 volts is associated with the active dissolution of gold.
  • FIG. 3 is a perspective diagram of one embodiment of a reservoir covered by a membrane having a current distribution network.
  • FIG. 4 is a plan view of twelve possible designs of springs to fabricate onto the reservoir caps of microchip devices, wherein the springs serve as stress-inducing structures to facilitate disintegration/rupture of the reservoir caps.
  • FIG. 5 is a cross-sectional view of one embodiment of a microchip device having a spring stress inducing structure.
  • DETAILED DESCRIPTION OF THE INVENTION
  • It has been discovered that reservoir cap opening in microchip devices can be enhanced by a number of means. Generally speaking, these means include a current distribution means, a stress induction means, or both, operably engaged with or integrated into the reservoir cap, to enhance reservoir cap disintegration.
  • I. Non-Uniformity of Thin Film Dissolution/Corrosion
  • Experiments have shown that the electrochemical dissolution rate of some metal membranes may not be uniform or complete across the surface of the membrane. Scanning electron micrographs taken of a partially dissolved gold membrane show the corners and edges of the membrane can corrode more than the interior surface, leaving for example a “flap” of gold still attached to one edge of the electrode. Such a flap may fold over and expose the reservoir opening or may remain in place and partially occlude the reservoir. Other membranes may corrode or dissolve to a certain thickness and then stop before the membrane is structurally weak enough to fall apart or disintegrate. This “residual” membrane may have enough strength to remain intact, thereby hindering or preventing the opening of the reservoir and the release of molecules or exposure of devices contained therein.
  • It is hypothesized that non-uniform or incomplete corrosion of thin metal membranes, such as those serving as reservoir caps, is due to one or a combination of five causes. The first cause is the presence of a non-uniform potential distribution across the surface of the membrane. The potential near the edge is fixed by the material (e.g., glass, silicon) covering the trace (e.g., gold) that supplies electric current to the membrane. However, the electrical resistivity of the membrane rises as it thins during the corrosion process, thus causing the electrical potential to vary across the exposed portion of the membrane, with the lowest potential occurring near the center of the membrane. The potential may become sufficiently low so that the gold corrosion reaction is no longer possible. For example, the potential vs. current diagram shown in FIG. 2 for a gold membrane in a dilute saline solution shows the current peak around 1.0-1.2 volts, which indicates gold corrosion is occurring. The diagram shows that a small decrease in electric potential will cause the corrosion reaction to dramatically decrease or even stop, as indicated by a sharp drop in current. This phenomenon is similar to non-uniform deposition during metal plating processes where the potential drop along metal traces influences the local deposition rate of metal.
  • The second suspected cause of variation in the rate and degree of metal membrane corrosion is the possible presence of local variations in the composition of the electrolyte at the surface of the metal film. The corrosion process can cause local variations in the composition, pH, and/or temperature of the electrolyte when transport of reactants to the metal surface and/or transport of products away from the metal surface are limited. Such variations in the electrolyte may then result in local surface corrosion rates that differ significantly from corrosion rates of the metal exposed to the bulk electrolyte. Such variations in the electrolyte often occur in or near physical defects such as pits, cracks, crevices, or hillocks, or fabricated structures such as trenches, holes, the interface between two layers of material, or any other location where mass transport may be hindered.
  • The third possible cause of variation in the rate and degree of uniformity of corrosion of thin metal membranes in microchips is related to their structural morphology, in particular grain size within the metal. For example, gold thin films have been shown to corrode preferentially in grain boundaries with an applied potential in dilute saline solutions (Santini, “A Controlled Release Microchip”, Ph.D. Thesis, Massachusetts Institute of Technology, 1999). Increased rates of corrosion in metal grain boundaries can cause portions of the metal film to be isolated from the source of electric potential, resulting in the local stoppage of corrosion. This is a particularly common problem for metal films whose thickness is only one grain thick, because corrosion through the thickness of the membrane or thin film can occur faster than the bulk of the membrane corrodes, which can hinder the passage of current through the membrane and stop the corrosion of the membrane prematurely, thereby potentially leaving portions of the metal membrane un-corroded and intact to hinder chemical release from the reservoirs of the microchip.
  • The fourth cause is changing internal stress in the metal membrane. Internal mechanical stress in the metal film can influence the corrosion rate. As the film is disintegrated, the force of this stress increases inversely with the decreasing thickness of the film, thereby creating micro-fractures, which expose more surface area to be disintegrated. In addition, stresses at the corners or along the edges of the membrane may be much higher than other regions of the membrane, leading to non-uniform, stress dependent variations in corrosion of the membrane.
  • The fifth cause of variation is related to the fabrication of thin metal film electrodes. The electron beam and sputtering processes used to deposit thin metal films result in surfaces that are relatively smooth on the atomic scale. This yields inefficient charge transfer and low currents for the geometric areas occupied by the film. In addition, the microfabrication processes used to make the microchip devices may introduce contaminants that adhere strongly to the metal electrode surfaces. Contaminants and the smooth surface of the electrodes can create non-uniform corrosion of the membrane electrodes. Specifically, when an anodic potential sufficient to corrode the metal is applied to the membrane, only a small amount of corrosion occurs until the surface roughens. Instabilities are created when localized regions (for example, the corners of the membrane) roughen before the remainder of the film. These regions have a much higher charge transfer rate and corrode faster. The entire process leads to non-uniform corrosion of the membrane. Removal of these contaminants and roughening of the metal surface will generally result in better electrochemical activity and corrosion.
  • II. Methods and Devices for Enhanced Reservoir Cap Disintegration
  • In a preferred embodiment, the microchip device for the controlled release or exposure of molecules or secondary devices comprise: (1) a substrate having a plurality of reservoirs; (2) reservoir contents comprising molecules, a secondary device, or both, located in the reservoirs; (3) reservoir caps positioned on the reservoirs over the reservoir contents; (4) electrical activation means for disintegrating the reservoir cap to initiate exposure or release of the reservoir contents in selected reservoirs; and a current distribution means, a stress induction means, or both, operably engaged with or integrated into the reservoir cap, to enhance reservoir cap disintegration.
  • As used herein, the terms “electrical activation” in reference to means for disintegrating refers to reservoir cap disintegration that is initiated by application of an electrical current or potential. This disintegration can be primarily as due to electrochemical action or thermal action (i.e., can occur electrochemically or thermally). Electrochemical disintegration occurs when the microchip device is in the presence of an electrolytic solution and comprises a cathode and an anodic reservoir cap (e.g., a thin metal film) and the electrical activation means applies an electric potential between the cathode and the anode effective to cause the reservoir cap to corrode and fall apart, as described for example in U.S. Pat. No. 5,797,898. Thermal activation occurs when the microchip device comprises at least one resistor (i.e., resistive heater) operably adjacent the reservoir cap and the electrical activation means applies an electric current through the resistor effective to heat the reservoir cap or contents enough to cause the reservoir cap to rupture, melt, or otherwise lose structural integrity, as described in U.S. Pat. No. 6,527,762. The device also can be configured so that the heating induces stress forces in the reservoir cap to facilitate mechanical failure. By “operably adjacent” is meant that the resistor is inside the reservoir, or attached to or otherwise sufficiently near the reservoir cap, to transfer an effective amount of heat to the reservoir cap or to the reservoir contents. These types of disintegration can occur together. For example, heating at the reservoir cap can increase the rate of the electrochemical reaction.
  • A. Current Distribution Means
  • The current distribution means includes, but is not limited to, structures designed to disperse electrical current and/or thermal energy uniformly across the reservoir cap, as well as structures that increase the exchange current density of reservoir caps that operate as electrodes. Representative current distribution means include current distribution networks and electrochemically plated metal layers (on the outer surface of the reservoir cap) that have increased surface roughness relative to the outer surface of the reservoir cap.
  • Current Distribution Networks
  • Effective disintegration is enhanced by providing the thin film with a current distribution network, such as one comprised of a plurality of traces attached to the outer surface of the thin film. The traces (which are strips of metal or another conductor fabricated onto the reservoir caps) and the thin film can be formed of the same material, such as gold, or the traces can be formed of a first material that corrodes at a different rate than a second material of which the thin film is formed. The traces could also be made of a conducting material that does not corrode, such as platinum, titanium, or silicon doped with ionic species. Alternatively, the traces can be coated with a passivating layer, such as one formed of silicon nitride, silicon oxide, or titanium oxide, to aid in the uniform distribution of the corrosion current across the surface of the thin film.
  • When electrochemical disintegration is to be employed, the current distribution network is a low electrical resistance path on top of, under, or near the membrane (reservoir cap). The current distribution network continues to conduct electricity throughout the duration of the corrosion process, even if the majority of the thin film or membrane anode is losing or has lost its ability to conduct electricity. When thermal disintegration is to be used, the current distribution network is a high electrical resistance path on top of, under, or near the membrane (reservoir cap). That is, it is essentially a resistor that heats the reservoir cap material or the reservoir contents.
  • In a preferred embodiment, a current distribution network is provided on or below the metal membrane (reservoir cap) in order to corrode the metal membrane more uniformly, minimizing the effects of some or all of the non-uniformity factors described above. One embodiment of this network is shown in FIG. 3, which shows current distribution network 10 (which is composed of numerous network traces) fabricated on top of the metal membrane 12 covering reservoir 14. Main trace 16, on substrate 18, provides current to the current distribution network 10 and metal membrane 12. A wide variety of network topologies are suitable. The main traces and network traces can be fabricated from the same or different materials.
  • The network traces can be current conductor paths that either do not corrode at the potential applied to the membrane or are so thick that their change in resistivity does not change significantly over the period during which they are corroded. Thus, the voltage drop along these traces is insignificant over the period in which the membrane is corroding. The traces simply act as current distribution “busses.” These traces can be located either on top of or below the membrane.
  • The trace spacing should be chosen to insure that the potential affected zone of the membrane is always close to one of the traces. This spacing can be established by measurement of the membrane resistivity as a function of thickness and by knowledge of the membrane thickness at which the membrane no longer retains structural integrity. The membrane resistivity will rise rapidly as the film becomes thinner. The resistivity at the failure thickness and the applied current density will establish the potential drop over film between the traces. This current distribution network will also form numerous crevices along the surface of the membrane. If crevice corrosion is indeed a significant contributor to corrosion for the particular metal/electrolyte system, then this process will allow the membrane to corrode more reproducibly by increasing the surface areas at which the membrane will corrode, perforate, and thereby expose and release molecules or devices from the reservoir.
  • In another preferred embodiment, a current distribution network is provided on top of the metal membrane (reservoir cap) by suitably patterning an insulating layer, in order to allow the portions of the membrane below the insulating layer to corrode slower, enabling those portions of the membrane to remain at the corrosion potential and distribute the corrosion current to neighboring exposed membrane surfaces as they become thinner. Preferred materials for such non-conducting layers include oxides and nitrides of silicon, titanium, and chromium, carbides, diamond-like materials, and certain organic compounds such as photopolymers (photoresists, polyimide), fluoropolymers (e.g. TEFLON™) and some epoxies.
  • Distribution Network Traces
  • The traces may be composed of several different types of materials. In one embodiment, the network traces are composed of the same material as the membrane or film, such as gold or other metals described above. In this embodiment, however, the traces are substantially thicker in cross-sectional area, such that the traces will corrode when the potential is applied, but the change in resistivity will be small compared to that which occurs in the membrane.
  • In another embodiment, the network traces are fabricated from a metal that does not corrode at the same potential as the membrane material. For example, platinum or titanium trace materials can be used with gold membranes.
  • In still another embodiment, the network traces are metal coated with a passivating layer to prevent degradation or corrosion. In a preferred form of this embodiment, gold network traces are coated with silicon oxide or silicon nitride dielectrics. In another variation, a current distribution network is provided on top of the metal membrane (reservoir cap) by patterning an insulating layer, in order to allow the portions of the membrane below the current distribution network to corrode slower, enabling those portions of the membrane to remain at the corrosion potential and distribute the corrosion current to neighboring exposed membrane surfaces as they become thinner. Preferred materials for such non-conducting layers include oxides and nitrides of silicon, titanium, and chromium, carbides, diamond-like materials, and certain organic compounds such as fluoropolymers (e.g. polytetrafluoroethylene) and some epoxies.
  • Increased Surface Roughness
  • In another embodiment, the current distribution means includes a reservoir cap or a layer thereon having a roughened metal surface for distributing current uniformly across the surface of the anode. The roughened surface transfers charge efficiently and should result in more uniform corrosion. Typically, the roughening method involves either repeated potential cycling through the metal oxide formation and stripping regions or repeated cycling in a metal complexing solution such as that containing a halide salt. The first method drives oxygen many atomic lengths into the surface and then removes it, potentially in combination with some metal. The latter method specifically dissolves and redeposits metal.
  • In one embodiment, roughening of the metal anode surface is obtained by plating a small amount of metal under conditions that should yield a nonepitaxial film. In the case of gold anodes, for example, a solution containing a mildly oxidizing, non-halide containing electrolyte such as HNO3, KNO3, H2SO4, Na2SO4 is prepared at a concentration between 0.01 and 5 M. To this solution, a small amount of HAuCl4 or other gold salt is added. The concentration of the gold salt should be in the range of 1 to 500 nM per cm2 of gold surface area on the device of interest. This concentration range ensures that no more than a few hundred atomic layers of gold will be deposited. The gold-containing device is then externally connected to a potential source such as a potentiostat. The device is then immersed in the above solution along with a counter and working electrode. The counter electrode is a clean, large surface area gold wire, sheet or mesh, which can act as an additional gold ion source. The most useful reference electrodes for this procedure are non-halide containing electrodes such as Hg|Hg2SO4|K2SO4 or Hg|HgO|NaOH. Physically isolating the reference electrode by placing it in a beaker connected by a salt bridge or Luggin capillary will minimize contamination. After immersion and electrical connection, a potential waveform (i.e., a square, triangular, or saw-tooth) is applied to the system using the standard three-electrode electrochemical cell geometry. This waveform scan or step is bounded by an upper potential limit of 1.0 to 2.0 V and a lower limit of −0.5 to 0.5 V. The upper limit is in the range where some oxide formation will occur. The lower limit is below the oxide-stripping region and also below the gold reduction region. The presence of the small quantity of gold salt in the solution prevents substantial dissolution of gold and provides material to be plated on the existing gold surface. After continued potential cycling for a period of 10 seconds to 1 hour, the cycling is stopped at the lower potential limit. The device is then withdrawn from the gold solution under potential control at this lower limit. This will ensure that the open circuit potential does not allow removal or oxidation of the gold immediately before withdrawal.
  • Electrochemical dissolution of a reservoir cap can be enhanced by cleaning and roughening the electrode surface. Examples of techniques for surfacing roughening include (1) increasing the electrode surface area by electrochemically plating metal onto the surface of the electrode prior to use, and (2) repeatedly cycling the metal electrode through the oxide formation and stripping potentials.
  • B. Stress Induction Means
  • Internal stress in the reservoir cap can be controlled, induced, and distributed by several techniques. When the metal film is fabricated, its initial tension can be adjusted by varying the shape of the support layer used in the deposition of the metal. For example, a flat support will result in a higher residual stress than a concave or convex support layer because the flat support will produce a tighter film when the film cools. Also, additional thickness of metal could be added to known high stress areas, such as corners, to extend the time required for sufficient disintegration in these areas where disintegration would occur at a faster rate due to the combination of the primary [electro] corrosion and the stress which is creating micro fractures. The stress can be controlled by patterning another material (conducting or non-conducting) on either or both sides of the metal film. This process would retard disintegration selectively and would reinforce the metal film in specific locations. For example, a pattern of the top surface dielectric that is used to insulate the electrical conductors that has rounded corners where it terminates at the periphery of the metal caps would produce less localized stress than sharp (e.g., 90°) corners. A pattern that extended over the central area of the metal cap could also distribute loading, thereby reducing local stress concentration.
  • Another factor that will control the magnitude and sign (tension vs. compression) of these stresses is the thermal processing history of the film. Thermal stresses can develop from a difference in thermal expansion between the film and the substrate on cooling the film from process temperature(s) to room temperature. By controlling the thermal cycle and engineering specific thermal mismatch differences, one can target specific stressed states.
  • In one embodiment, the stress inducing means comprises a pre-stressed structure that enhances reservoir cap opening, for example, as the reservoir cap thermally or electrochemically disintegrates. The pre-stressed structure preferably provides a force substantially perpendicular to the surface of the reservoir cap.
  • The pre-stressed structure can be a member attached to (e.g., built upon) or integrated into the reservoir cap. Residual stress in the structure, in its simplest form, a cantilever beam, loads the membrane. The intact membrane counteracts the stress. As the membrane corrodes and weakens, the stress introduced by the structure exceeds the yield strength of the corroded membrane and the structure penetrates the membrane.
  • In one embodiment, the pre-stressed structure is a cantilever beam, e.g., located on a thin film anode. This beam will cause the reservoir to open if the anode corrodes or dissolves to a certain thickness and then stops before the membrane is structurally weak enough to fall apart. In other embodiments, the pre-stressed structure can comprise a single layer of material having a stress gradient, or the pre-stressed structure can comprise a spring, coil, or cross design (see FIGS. 4 and 5), as well as a variety of other configurations.
  • In another approach, a structure is fabricated as a composite of two layers having residual stress of opposite sign. That is, one layer having a built-in tensile stress, while the other having a compressive stress. The means to control stress in thin films deposited during microfabrication is well known. For example, the stress of films deposited using plasma-enhanced chemical vapor deposition (PECVD) is controlled by controlling the temperature of the deposition, and the composition of the gases used to form the film. A suitable structure can be formed of a composite layer of silicon dioxide having a compressive stress, and a layer of silicon nitride having a tensile stress.
  • By controlling internal stress levels and the distribution of internal stresses in the metal film, a more consistent corrosion result can be achieved. Stress levels can be controlled by, for example, varying the dimensions of the metal film (including thickness), its grain size and crystal orientation, the film's intrinsic stress (affected by parameters such as temperature, pressure, and method of deposition), and its initial tension loading, as well as by selective patterning of other materials on the top and/or bottom surfaces of the metal film to direct the stress loading of the film (while still exposing a sufficient amount of metal film to achieve effective disintegration).
  • C. Controlled Morphology of the Metal Membrane
  • Where grain boundary corrosion is a dominant cause of non-uniform corrosion and molecule release, reliability and uniformity can be improved by changing the structural morphology (i.e., average grain size distribution and grain orientation distribution) of the metal membrane itself. Specifically, decreasing the size of the metal grains with respect to the thickness of the membrane should improve corrosion of the membrane, and thus opening of the reservoir and release of molecules. This grain size change will increase the proportion of the membrane mass and metal surface area consisting of grain boundaries with respect to the mass and metal surface area consisting of grains. Therefore, preferential corrosion of the grain boundaries will cause a larger portion of the membrane to corrode, leaving a membrane that is weaker and more likely to open after corrosion by an applied potential.
  • There are numerous methods (e.g., plasma-deposition or evaporation-deposition) with several parameters (e.g., impurity level, temperature, and deposition potential) to keep grain sizes small in thin films. See for example, Thompson, “Grain Growth in Thin Metal Films,” Annu. Rev. Mater. Sci., 20: 45-68 (1990); King & Harris, “Grain Growth Suppression and Enhancement by Interdiffusion in Thin Metal Films”, Mat. Res. Soc. Symp. Proc., 343: 3-42 (1994). In one embodiment, the metal is deposited at a higher base pressure (e.g., lower base vacuum), which typically is greater than 10−5 Torr. This allows oxygen and other impurities in the deposition chamber to be incorporated into the metal film. These impurities can slow grain boundary mobility and grain growth. Impurities can also be introduced into grain structure by solution doping. “Impurities” present in solution are capable of strongly influencing the grain growth rate, since they will tend to segregate to the grain boundaries and exert a drag force on boundary motion. These impurities can also be in the form of precipitates. The grain boundaries must move past the precipitates during growth, which results in a local increase in interfacial energy that acts as an impeding force on the grain boundary.
  • The thermal processing of the metal film is a critical factor that dictates the average grain size and the size distribution because grain boundary mobility is strongly temperature dependent, Mgrain∝exp(−E/kT). Therefore, grain size can be kept small by limiting thermal processing of the thin film after deposition, as high temperatures can induce high grain growth rates, i.e., large grains. Maintaining low temperatures during processing, T<0.2*TMelt, will promote a smaller average grain size (10 to 100 nm), while higher temperatures, T>0.2*TMelt, will yield larger grains (≧1000 nm).
  • Since corrosion may occur primarily at the “amorphous” grain boundaries, the gold film may preferably be amorphous rather than polycrystalline. This may be achieved by impurity doping and/or rapid cooling in excess of 108 K/sec during processing (Schaffer, et al., The Science and Design of Engineering Materials, p. 225, Irwin Inc. (Chicago 1995)). Another potential method for producing amorphous metal films involves bombarding the metal film during deposition with an ion beam.
  • Effective disintegration is enhanced by controlling the size of the grains in the metal film. For example, the longest dimension of metal grains possibly may be made smaller than the thickness of the film. Small grain size can be achieved, for example, by forming the metal film via deposition at a high base pressure (i.e., lower base vacuum). Large grain size, if desired, can be achieved by deposition of the metal film at high vacuum. Grain size may also be modified by impacting the thin film with an ion beam during deposition. Small grain size can be maintained by avoiding exposure to high temperatures following deposition of the metal film, while grains can be made larger by post-deposition heat treatment.
  • III. The Basic Microchip Devices
  • As used herein, a “microchip” is a miniaturized device fabricated using methods commonly applied to the manufacture of integrated circuits such as ultraviolet (UV) photolithography, reactive ion etching, and electron beam evaporation, as described, for example, by Wolf & Tauber, Silicon Processing for the VLSI Era, Volume 1—Process Technology (Lattice Press, Sunset Beach, Calif., 1986); and Jaeger, Introduction to Microelectronic Fabrication, Volume V in The Modular Series on Solid State Devices (Addison-Wesley, Reading, Mass., 1988), as well as MEMS methods that are not standard in making computer microchips, including those described, for example, in PCT WO 01/41736; Madou, Fundamentals of Microfabrication (CRC Press 1997); and other micromolding and micromachining techniques known in the art. The microchips provide control over the rate the molecules are released as well as the time at which release begins. The time of release can be controlled actively or passively.
  • The microchip fabrication procedure allows the manufacture of devices with primary dimensions (length of a side if square or rectangular, or diameter if circular) ranging from less than a millimeter to several centimeters. Typical device thicknesses range from 300 to 550 μm. However, the thickness of the device can vary from approximately 10 μm to several centimeters, depending on the device's application. Total device thickness and reservoir volume can also be increased by bonding (for example, by anodic bonding) or attaching (for example, by adhesives) additional silicon wafers or other substrate materials (such as glasses or plastics) having openings or apertures that align with the reservoirs to the fabricated microchip device. In general, changing the device thickness affects the volume of each reservoir and may affect the maximum number of reservoirs that may be incorporated onto a microchip. In vivo applications of the device typically require devices having a primary dimension of 5 cm or smaller. Devices for in vivo applications may be made small enough to be swallowed or implanted using minimally invasive procedures. Smaller in vivo devices (on the order of a millimeter) can be implanted using a catheter or other injectable means. Devices for in vitro applications have fewer size restrictions and, if necessary, can be made much larger than the dimension ranges for in vivo devices.
  • IV. Device Components and Materials
  • Each device consists of a substrate, reservoirs, and a release system containing, enclosing, or layered with the molecules to be delivered. The device further includes a reservoir cap to control the release or exposure time of the molecules or devices contained in the reservoirs, and typically includes control circuitry and a power source for active microchips. The substrate, reservoirs, release system, reservoir contents, control circuitry and power source are substantially as described in U.S. Pat. No. 5,797,898 and No. 6,123,861, as well as PCT WO 02/30401, WO 02/30264, WO 01/91902, WO 01/64344, WO 01/41736, WO 01/35928, and WO 01/12157.
  • A. The Substrate
  • The substrate contains the etched, machined, or molded reservoirs and serves as the support for the microchip. Any material which can serve as a support, is suitable for etching, machining, or molding, and is impermeable (during the time scale of the microchip's use) to the molecules to be delivered and to the surrounding fluids (e.g., water, blood, electrolytes or other solutions) may be used as a substrate. Examples of substrate materials include metals, ceramics, semiconductors, and degradable and non-degradable polymers. Biocompatibility of the substrate material is preferred, but not required. For in vivo applications, non-biocompatible materials may be encapsulated or contained in a biocompatible material, such as poly(ethylene glycol), polytetrafluoroethylene-like materials, or titanium, before use. One example of a strong, non-degradable, easily etched substrate that is impermeable to the molecules to be delivered and the surrounding fluids is silicon. In another embodiment, the substrate is made of a strong material that degrades or dissolves over a defined period of time into biocompatible components. This embodiment is preferred for in vivo applications where the device is implanted and physical removal of the device at a later time is not feasible or recommended, for example, brain implants. An example of a class of strong, biocompatible materials are the poly(anhydride-co-imides) described in Uhrich et al., “Synthesis and characterization of degradable poly(anhydride-co-imides)”, Macromolecules, 28: 184-93 (1995). Another group of biocompatible polymers suitable for use as a substrate material includes PLA [poly(lactic acid)], PGA [poly(glycolic acid)], and PLGA [poly(lactic-co-glycolic acid)].
  • B. Molecules and Secondary Devices (Reservoir Contents)
  • The reservoirs contain molecules, secondary devices, or combinations thereof, that need to be protected from surrounding environmental components until their release or exposure is desired. Proper functioning of certain reservoir contents, such as a catalyst or sensor, generally does not require their release from the reservoir; rather their intended function, e.g., catalysis or sensing, occurs upon exposure of the reservoir contents to the environment outside of the reservoir after opening of the reservoir cap. Thus, the catalyst molecules or sensing component can be released or can remain immobilized within the open reservoir.
  • Molecules
  • The reservoir contents can include essentially any natural or synthetic, organic or inorganic molecule or mixture thereof, for release (i.e., delivery) or retained and exposed. The molecules (i.e., chemicals) may be in pure solid, liquid, or gel form, or mixed with other materials that affect the release rate and/or time. Chemicals may be in the form of solid mixtures including, but not limited to, amorphous and crystalline mixed powders, monolithic solid mixtures, lyophilized powders, and solid interpenetrating networks; in the form of liquid mixtures including, but not limited to, solutions, emulsions, colloidal suspensions, and slurries; and in the form of gel mixtures including, but not limited to, hydrogels.
  • For in vivo applications, the chemical preferably is a therapeutic, prophylactic, or diagnostic agent. In one embodiment, the microchip device is used to deliver drugs systemically to a patient in need thereof. In another embodiment, the construction and placement of the microchip in a patient enables the local or regional release of drugs that may be too potent for systemic delivery of an effective dose. As used herein, “drugs” include any therapeutic, prophylactic or diagnostic agent, including organic or inorganic molecules, proteins, nucleic acids, polysaccharides and synthetic organic molecules, having a bioactive effect. Representative examples include analgesics, steroids, cytokines, psychotropic agents, chemotherapeutic agents, and hormones anesthetics, vaccines, metabolites, sugars, immunomodulators, antioxidants, ion channel regulators, and antibiotics. An example of a diagnostic agent is an imaging agent such as a contrast agent. The drugs can be in the form of a single drug or drug mixtures and can include pharmaceutically acceptable carriers.
  • In another embodiment, molecules are released in vitro in any system where the controlled release of a small (milligram to nanogram) amount of one or more molecules is required, for example, in the fields of analytic chemistry or medical diagnostics. Molecules can be effective as pH buffering agents, diagnostic reagents, and reagents in complex reactions such as the polymerase chain reaction or other nucleic acid amplification procedures.
  • In another embodiment, the molecules to be released are perfumes, fragrances, dyes, coloring agents, sweeteners, or a variety of other compounds, which for example, may be useful to release as a function of temperature change.
  • In other embodiments, the reservoirs contain immobilized molecules. Examples include any chemical species which can be involved in a reaction, including, but not limited to, reagents; catalysts, including enzymes, metals, and zeolites; proteins; nucleic acids; polysaccharides; polymers; cells, as well as organic or inorganic molecules, including diagnostic agents.
  • Formulations of molecules to be released also may contain stabilizers and anti-oxidants to preserver the integrity of the drug or other molecules.
  • Molecules to be delivered may be inserted into the reservoirs in their pure form, as a liquid solution or gel, or as a material that quickly vaporizes. Alternatively, the molecules may be encapsulated within or by a release system. As used herein, “release system” includes both the situation where the molecules are in pure form, as either a solid, liquid, or vapor, or are formulated in a matrix formed of a degradable material or a material that releases incorporated molecules by diffusion out of or disintegration of the matrix. The degradation, dissolution, or diffusion properties of the release system can provide a method for controlling the release rate of the molecules. The molecules can be homogeneously or heterogeneously distributed within the release system. Selection of the release system is dependent on the desired rate of release of the molecules.
  • Both non-degradable and degradable release systems can be used for delivery of molecules. Suitable release systems include polymers, polymeric matrices, non-polymeric matrices, and inorganic and organic excipients and diluents. Examples of such excipients and diluents include calcium carbonate and sugar. Release systems may be natural or synthetic, although synthetic release systems are preferred due to the better characterization of release profiles. The release system is selected based on the period over which release is desired, generally in the range of at least one to twelve months for in vivo applications. In contrast, release times as short as a few seconds may be desirable for some in vitro applications. In some cases, continuous (constant) release from a reservoir may be most useful. In other cases, pulsed (variable) release from a reservoir may provide results that are more effective.
  • Pulsatile release can be achieved from an individual reservoir, from a plurality of reservoirs, or a combination thereof. For example, where each reservoir provides only a single pulse, multiple pulses (i.e., pulsatile release) are achieved by temporally staggering the single pulse release from each of several reservoirs. Alternatively, multiple pulses can be achieved from a single reservoir by incorporating several layers of a release system and other materials into a single reservoir.
  • Continuous release can be achieved by incorporating a release system that degrades, dissolves, or allows diffusion of molecules through it over an extended period. In addition, continuous release can be approximated by releasing several pulses of molecules in rapid succession (“digital” release, analogous to the digital storage and reproduction of music).
  • Active and passive release systems can be combined. For example, a metal film or membrane reservoir cap, which is removed actively, can cover a passive release system that only begins its passive release after the metal film has been actively removed. Alternatively, a given substrate can include both passive and active release reservoirs.
  • The release system material can be selected so that molecules of various molecular weights are released from a reservoir by diffusion out or through the material or degradation of the material. Biodegradable polymers, bioerodible hydrogels, and protein delivery systems are preferred for release of molecules by diffusion, degradation, or dissolution. In general, these materials degrade or dissolve either by enzymatic hydrolysis or exposure to water in vivo or in vitro, or by surface or bulk erosion. Representative synthetic, biodegradable polymers include polyamides such as poly(amino acids) and polypeptides; polyesters such as poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), and polycaprolactone; polyanhydrides; polyorthoesters; polycarbonates; and chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof. Representative synthetic, non-degradable polymers include polyethers such as poly(ethylene oxide), poly(ethylene glycol), and poly(tetramethylene oxide); vinyl polymers—polyacrylates and polymethacrylates such as methyl, ethyl, other alkyl, hydroxyethyl methacrylate, acrylic and methacrylic acids, and others such as poly(vinyl alcohol), poly(vinyl pyrolidone), and poly(vinyl acetate); polyurethanes; cellulose and its derivatives such as alkyl, hydroxyalkyl, ethers, esters, nitrocellulose, and various cellulose acetates; polysiloxanes; and any chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), copolymers and mixtures thereof.
  • Secondary Devices
  • As used herein, unless explicitly indicated otherwise, the term “secondary device” includes, but is not limited to, any device and component thereof which can be located in or designed to operably communicate with one or more reservoirs in a microchip device. In a preferred embodiment, the secondary device is a sensor or sensing component. As used herein, a “sensing component” includes, but is not limited to, a component utilized in measuring or analyzing the presence, absence, or change in a chemical or ionic species, energy, or one or more physical properties (e.g., pH, pressure) at a site. Types of sensors include biosensors, chemical sensors, physical sensors, or optical sensors. Secondary devices are further described in PCT WO 01/64344.
  • Examples of sensing components include components utilized in measuring or analyzing the presence, absence, or change in a drug, chemical, or ionic species, energy (or light), or one or more physical properties (e.g., pH, pressure) at a site. In a preferred embodiment, the microchip device is implantable in a patient (e.g., a human or other mammal) and includes sensors for monitoring the levels of glucose or urea in blood and other body fluids.
  • There are several different options for receiving and analyzing data obtained with devices located in the microchip devices. Typically, the operation of the microchip system will be controlled by an on-board (i.e., within the package) microprocessor. The output signal from the device, after conditioning by suitable circuitry if needed, will be acquired by the microprocessor. After analysis and processing, the output signal can be stored in a writeable computer memory chip, and/or can be sent (e.g., wirelessly) to a remote location away from the microchip. Power can be supplied to the microchip system locally by a microbattery or remotely by wireless transmission.
  • D. Reservoir Caps
  • The reservoir cap is positioned on the reservoir over the molecules to be released. In one embodiment, a reservoir cap is positioned on top of the release systems contained in one or more reservoirs.
  • Metal Films
  • In a preferred embodiment, the reservoir cap is in the form of a thin metal film (also herein referred to as a metal membrane). Representative examples, of suitable metal materials include copper, gold, silver, zinc, and combinations thereof. The reservoir cap optionally can be coated with an overcoat material, for example to protect the metal from premature degradation until the overcoat material has been substantially removed by dissolving, eroding, biodegrading, oxidizing, or otherwise degrading, such as upon exposure to water in vivo or in vitro. Representative suitable degradable materials include synthetic or natural biodegradable polymers.
  • The metal films may be reinforced with a pattern of a second material (frequently dissimilar to the metal) deposited onto surfaces of the film in order to strengthen the film and/or to distribute mechanical stress. The second material can be deposited on the surface adjacent the reservoir (i.e., the inner surface) or distal the reservoir (i.e., the outer surface).
  • For thermal disintegration, the reservoir cap can be a non-conducting material.
  • E. Device Packaging, Control Circuitry, and Power Source
  • Microelectronic device packages are typically made of an insulating or dielectric material such as aluminum oxide or silicon nitride. Their purpose is to allow all components of the device to be placed in close proximity and to facilitate the interconnection of components to power sources and to each other. For in vivo applications of the delivery device, the entire package, including all components (i.e., the device, the microprocessor, and the power source), are contained, coated, or encapsulated in a biocompatible material such as poly(ethylene glycol), polytetrafluoroethylene-like materials, or titanium. The materials requirements for in vitro applications may be less stringent and depend on the particular situation.
  • The control circuitry typically consists of a timer, a demultiplexer, a microprocessor, an input source (for example, a memory source, a signal receiver or a biosensor), and a power source. The timer and demultiplexer circuitry can be designed and incorporated directly onto the surface of the microchip during electrode fabrication. The criteria for selection of a microprocessor are small size, low power requirement, and the ability to translate the output from memory sources, signal receivers, or biosensors into an address for the direction of power through the demultiplexer to a specific reservoir on the delivery device. Selection of a source of input to the microprocessor such as memory sources, signal receivers, or biosensors depends on the delivery device's particular application and whether device operation is preprogrammed, controlled by remote means, or controlled by feedback from its environment (i.e., biofeedback).
  • The criteria for selection of a power source are small size, sufficient power capacity, ability to be integrated into the control circuitry, ability to be recharged, and the length of time before recharging is necessary. Several lithium-based, rechargeable microbatteries have been described in Jones & Akridge, “Development and performance of a rechargeable thin-film solid-state microbattery”, J. Power Sources, 54: 3-67 (1995); and Bates et al., “New amorphous thin-film lithium electrolyte and rechargeable microbattery”, IEEE 35th International Power Sources Symposium, pp. 337-39 (1992). These batteries are typically only ten microns thick and occupy 1 cm2 of area. One or more of these batteries can be incorporated directly onto the delivery device. Alternatively, a capacitor can be charged by transduction of microwave, RF, or sonic energy.
  • V. Methods of Device Fabrication
  • The microchip devices can be made using the methods described below, alone or in combination with known methods, such the microfabrication techniques described in U.S. Pat. Nos. 5,797,898 and 6,123,861, to Santini, et al. Other methods are described in PCT WO 01/41736. For example, the substrate can be formed from polymer, ceramic, or metal, e.g., by compression molding powders or slurries of polymer, ceramic, metal, or combinations thereof. Other forming methods useful with these materials include injection molding, thermoforming, casting, machining, and other methods known to those skilled in the art. Substrates formed using these methods can be formed (e.g., molded) to have the reservoirs or the reservoirs can be added in subsequent steps, such as by etching.
  • Exemplary processes are described below.
  • A. Fabrication of Substrates with Reservoirs
  • In one method of microchip manufacture, fabrication begins by depositing and photolithographically patterning a material, typically an insulating or dielectric material, onto the substrate to serve as an etch mask during reservoir etching. Typical insulating materials for use as a mask include silicon nitride, silicon dioxide, and some polymers, such as polyimide. In a preferred embodiment, a thin film (approximately 1000-3000 Å) of low stress, silicon-rich nitride is deposited on both sides of a silicon wafer in a Vertical Tube Reactor (VTR). Alternatively, a stoichiometric, polycrystalline silicon nitride (Si3N4) can be deposited by Low Pressure Chemical Vapor Deposition (LPCVD), or amorphous silicon nitride can be deposited by Plasma Enhanced Chemical Vapor Deposition (PECVD). Reservoirs are patterned into the silicon nitride film on one side of the wafer by ultraviolet photolithography and either plasma etching or a chemical etch consisting of hot phosphoric acid or buffered hydrofluoric acid. The patterned silicon nitride serves as an etch mask for the chemical etching of the exposed silicon by a concentrated potassium hydroxide solution (approximately 20-40% KOH by weight at a temperature of 75-90° C.). Alternatively, the reservoirs can be etched into the substrate by dry etching techniques such as reactive ion etching or ion beam etching. These techniques are commonly used in the fabrication of microelectronic devices, as reviewed, for example, by Wolf et al. (1986), Jaeger (1988), and Madou (1997). Use of these microfabrication techniques allows the incorporation of hundreds to thousands of reservoirs on a single microchip. The spacing between each reservoir depends on its particular application and whether the device is a passive or active device. In a passive device, the reservoirs may be less than one micron apart. In an active device, the distance between the reservoirs may be slightly larger (greater than approximately 1 to 10 μm) due, for example to the space occupied by circuitry on or near each reservoir. Reservoirs can be made in nearly any shape and depth, and need not pass completely through the substrate. In a preferred embodiment, the reservoirs are etched into a (100) oriented, silicon substrate by potassium hydroxide, in the shape of a square pyramid having side walls sloped at 54.7°, and pass completely through the substrate (approximately 525 μm thick) to the silicon nitride film on the other side of the substrate, forming a silicon nitride membrane. (Here, the silicon nitride film serves as a potassium hydroxide etch stop.) The pyramidal shape allows easy filling of the reservoirs through the large opening of the reservoir (approximately 800 μm by 800 μm for a 525 μm thick wafer) on the patterned side of the substrate, release through the small opening of the reservoir (approximately 50 μm by 50 μm) on the other side of the substrate, and provides a large cavity inside the device for storing the drugs or other molecules to be delivered.
  • In a preferred embodiment of the active devices, resistors are integrated into the device. Typically, thin-film resistors are conveniently integrated with the reservoir during the manufacturing process, as the resistors commonly are made by deposition and patterning methods that are used to manufacture the reservoirs as described herein. Alternatively, small chip resistors can be surface mounted in close proximity to the reservoir.
  • B. Fabrication of Active Timed-Release Reservoir Caps
  • In a preferred embodiment, photoresist is patterned in the form of electrodes on the surface of the substrate having the reservoirs covered by the thin membrane of insulating or dielectric material. The photoresist is developed such that the area directly over the covered opening of the reservoir is left uncovered by photoresist and is in the shape of an anode. A thin film of conductive material capable of dissolving into solution or forming soluble ions or oxidation compounds upon the application of an electric potential is deposited over the entire surface using deposition techniques such as chemical vapor deposition, electron or ion beam evaporation, sputtering, spin coating, and other techniques known in the art. Exemplary materials include metals such as copper, gold, silver, and zinc, and some polymers, such as disclosed by Kwon et al. (1991) and Bae et al. (1994). After film deposition, the photoresist is stripped from the substrate. This removes the deposited film, except in those areas not covered by photoresist (lift-off technique). This leaves conducting material on the surface of the substrate in the form of electrodes. An alternative method involves depositing the conductive material over the entire surface of the device, patterning photoresist on top of the conductive film using UV or infrared (IR) photolithography, so that the photoresist lies over the reservoirs in the shape of anodes, and etching the unmasked conductive material using plasma, ion beam, or chemical etching techniques. The photoresist is then stripped, leaving conductive film anodes covering the reservoirs. The thickness of the conductive film typically, but not necessarily, is between about 0.05 and several microns. The anode serves as the reservoir cap and the placement of the cathodes on the device is dependent upon the device's application and method of electric potential control.
  • Alternatively, a reservoir cap material can be deposited that disintegrates, cracks, or ruptures in response to changes in the temperature of the cap material itself or in response to a temperature-induced pressure increase in the reservoir. Such caps can be made using techniques such as, but not limited to, spin coating, solvent casting, evaporation, chemical vapor deposition, sputtering, or other deposition methods known in the art. The contents of such as reservoir contains at least one material that expands or vaporizes when exposed to heat produced by a source within or in thermal communication with the reservoir or the material. Representative examples of such sources that can transmit energy to the material include resistive heating elements, piezeoelectric elements, capacitive discharge (spark) elements, and combinations thereof.
  • An insulating or dielectric material such as silicon oxide (SiOX) or silicon nitride (SiNX) is deposited over the entire surface of the device by methods such as chemical vapor deposition (CVD), electron or ion beam evaporation, sputtering, or spin coating. Photoresist is patterned on top of the dielectric to protect it from etching except on the cathodes and the portions of the anodes directly over each reservoir. The dielectric material can be etched by plasma, ion beam, or chemical etching techniques. The purpose of this film is to protect the electrodes from corrosion, degradation, or dissolution in all areas where electrode film removal is not necessary for release.
  • The electrodes are positioned in such a way that when an electric potential is applied between an anode and a cathode, the unprotected (not covered by dielectric) portion of the anode reservoir cap oxidizes to form soluble compounds or ions that dissolve into solution, exposing the reservoir contents to the surrounding fluids. The molecules are released from the reservoir at a rate dependent upon the degradation or dissolution rate of a degradable release system or the rate of diffusion of the molecules out of or through a non-degradable release system.
  • Alternatively, one or more resistors are positioned in the reservoirs or near the cap material so that passing a current through the resistor will change the temperature of the contents of the reservoir or the temperature of the cap material. A sufficient temperature change causes the reservoir to open by rupturing the cap due to an increase in the pressure in the reservoir, a change in the cap material itself based on its physical properties (e.g., volume changes with temperature related to its coefficient of thermal expansion), or a combination thereof.
  • C. Removal of the Insulator Membrane (Reservoir Etch Stop)
  • The thin membrane of insulating or dielectric material covering the reservoir used as a mask and an etch stop during reservoir fabrication must be removed from the active timed release device before filling the reservoir and from the passive timed release device (if the reservoir extends completely through the substrate) after filling reservoir. The membrane may be removed in two ways. First, the membrane can be removed by an ion beam or reactive ion plasma. In a preferred embodiment, the silicon nitride used as the insulating material can be removed by reactive ion plasma composed of oxygen and fluorine containing gases such as CHF3 or CF4. Second, the membrane can be removed by chemical etching. For example, buffered hydrofluoric acid (BHF or BOE) can be used to etch silicon dioxide and hot phosphoric acid can be used to etch silicon nitride.
  • D. Reservoir Filling
  • The release system containing the molecules for delivery is inserted into the large opening of the reservoir by injection, inkjet printing, screen printing, or spin coating. Each reservoir can contain a different molecule and dosage. Similarly, the release kinetics of the molecule in each reservoir can be varied by the choice of the release system and cap materials. In addition, the mixing or layering of release system and cap materials in each reservoir can be used to tailor the release kinetics to the needs of a particular application.
  • The distribution over the microchip of reservoirs filled with the release system containing the molecules to be delivered can vary depending on the medical needs of the patient or other requirements of the system. For applications in drug delivery, for example, the drugs in each of the rows can differ from each other. One row may contain a hormone and another row may contain a metabolite. In addition, the release system can differ within each row to release a drug at a high rate from one reservoir and a slow rate from another reservoir. The dosages can also vary within each row. For those devices having deep (greater than 10 μm) reservoirs or reservoirs with large (greater than 50 μm) openings, differences in reservoir loading can be achieved by injection or inkjet printing of different amounts of material directly into each reservoir. Variation between reservoirs is achieved in devices having shallow (less than 10 μm) reservoirs, reservoirs that do not pass completely through the substrate, or reservoirs with small (less than 50 μm) openings by a repeated, step-wise process of masking selected reservoirs, spin coating, and etching, as described above regarding the fabrication by spin coating of passive timed release reservoir caps. Preferably, the release system and molecules to be delivered are mixed before application to the reservoirs. Although injection, inkjet printing and spin coating are the preferred methods of filling reservoirs, it is understood that each reservoir can be filled individually by capillary action, by pulling or pushing the material into the reservoir using a vacuum or other pressure gradient, by melting the material into the reservoir, by centrifugation and related processes, by manually packing solids into the reservoir, or by any combination of these or similar reservoir filling techniques.
  • E. Device Packaging, Control Circuitry, and Power Source
  • The openings through which the reservoirs of passive and active devices are filled are sealed by wafer bonding or with a waterproof epoxy or other appropriate material impervious to the surrounding fluids. For in vitro applications, the entire unit, except for the face of the device containing the reservoirs and electrodes, is encased in a material appropriate for the system. For in vivo applications, the unit is preferably encapsulated in a biocompatible material such as poly(ethylene glycol) or polytetrafluoroethylene.
  • The mechanism for release of molecules by the active timed-release device does not depend on multiple parts fitted or glued together which must retract or dislodge. Control of the time of release of each reservoir can be achieved by a preprogrammed microprocessor, by remote control, by a signal from a biosensor, or by any combination of these methods.
  • First, a microprocessor is used in conjunction with a source of memory such as programmable read only memory (PROM), a timer, a demultiplexer, and a power source such as a microbattery, which is described, for example, by Jones et al. (1995) and Bates et al. (1992). The pre-selected release pattern is written in machine-readable form directly into the PROM by the user (e.g., the physician). These instructions are read from the PROM by the microprocessor, which takes appropriate action, such as starting a timer. When the time for release has been reached as indicated by the timer, the microprocessor sends a signal corresponding to the address (location) of a particular reservoir to the demultiplexer. The demultiplexer routes an input, such as an electric potential or current, to the reservoir addressed by the microprocessor. A microbattery provides the power to operate the PROM, timer, and microprocessor, and provides the electric potential or current input that is directed to a particular reservoir by the demultiplexer. The manufacture, size, and location of each of these components are dependent upon the requirements of a particular application. In a preferred embodiment, the memory, timer, microprocessor, and demultiplexer circuitry is integrated directly onto the surface of the chip. The microbattery is attached to the other side of the chip and is connected to the device circuitry by vias or thin wires. However, in some cases, it is possible to use separate, prefabricated, component chips for memory, timing, processing, and demultiplexing. These are attached to the backside of the miniaturized delivery device, or carrier substrate, with the battery. The size and type of prefabricated chips used depends on the overall dimensions of the delivery device and the number of reservoirs.
  • Second, activation of a particular reservoir by the application of an electric potential or current can be controlled externally by remote control. Much of the circuitry used for remote control is the same as that used in the preprogrammed method. The main difference is that the function of the PROM as a source of the dosing regime is replaced by a signal receiver. A signal (e.g., radio wave, microwave, low power laser, or ultrasound) is sent to the receiver by an external source, for example, a computer or an ultrasound generator. The signal is received by the microprocessor where it is translated into a reservoir address. Power is then directed through the demultiplexer to the reservoir having the appropriate address.
  • Third, a biosensor, which may or may not be integrated into the microchip, can detect molecules in the surrounding fluids or temperature or pressure. When the concentration of the molecules reaches a certain value or when a tissue temperature or fluid pressure is reached, the sensor sends a signal to the microprocessor to activate one or more reservoirs. The microprocessor directs power through the demultiplexer to the particular reservoir(s).
  • F. Electric Potential or Current Control Methods
  • The reservoir caps of an active device are anodes that oxidize to form soluble compounds and ions when a potential is applied between the anode and a cathode. For a given electrode material and electrolyte, there exists a range of electric potentials over which these oxidation reactions are thermodynamically and kinetically favorable. In order to reproducibly oxidize and open the reservoir caps of the device, the anode potential must be maintained within this favorable potential range.
  • There exist two primary control methods for maintaining an electrode within a specific potential range. The first method is called potentiostatic control. As the name indicates, the potential is kept constant during reservoir activation. Control of the potential is typically accomplished by incorporating a third electrode into the system that has a known, constant potential, called a reference electrode. The reference electrode can take the form of an external probe whose tip is typically placed within one to three millimeters of the anode surface. The potential of the anode is measured and controlled with respect to the known potential of a reference electrode such as a saturated calomel electrode (SCE), a silver/silver chloride (Ag/AgCl) electrode, or sometimes a platinum wire. In a preferred embodiment of potentiostatic control, a thin film reference electrode and potential feedback controller circuitry could be fabricated directly onto the surface of the microchip. For example, a microfabricated Ag/AgCl reference electrode integrated with a microchip device would enable the device to maintain the anode potential of an activated reservoir within the oxidation regime until the reservoir was completely opened. The second method is called galvanostatic control. As the name indicates, the current is kept constant during reservoir activation. One drawback of this method of control is that there is more than one stable potential for a given current density. However, if the current density versus potential behavior is well characterized for the microchip device in a particular electrolyte system, the current density that will maintain the anode in the oxidation regime will be known. In this case, the galvanostatic method of potential control would be preferable to the potentiostatic control, because galvanostatic control does not require a reference electrode.
  • Alternatively, corrosion can be achieved using less complicated means of controlling the potential. A reference electrode is not needed if the potential between the anode and the cathode is periodically swept through a range of potential such that the potential difference between the anode and the electrolyte needed for oxidative corrosion is achieved during the sweep. In other words, if the reference electrode is eliminated and the electrical potential is swept back and forth (i.e., cycled) over a suitable range, then the anode will experience the potential required for corrosion at least a fraction of the time. Corrosion will thus occur.
  • Another method of reservoir opening and chemical release is based on rupturing the reservoir cap due to a change in the temperature of the materials in the reservoir or a change in the temperature of the material forming the reservoir cap. In a preferred embodiment, such temperature changes are induced using thin film resistors integrated onto the microchip itself or small, prefabricated chip resistors surface mounted onto the microchip or its associated packaging. The temperature change may be controlled by the amount of current that is passed through the resistor and the thermal properties of the material inside the reservoir or the reservoir cap material. Control over the amount of current applied and its duration of application can be controlled by a microprocessor, remote control, biosensor, or a combination of these devices.
  • VI. Microchip Device Applications
  • The microchip device systems can be used in a wide variety of applications. The applications can be ex vivo or in vitro, but more preferably are for in vivo applications, particularly following non- or minimally-invasive implantation.
  • Preferred applications for using the devices and systems include the controlled delivery of a drug to sites within the body of a human or animal, biosensing, or a combination thereof. The microchip systems are especially useful for drug therapies in which it is desired to control the exact amount, rate, and/or time of delivery of the drug. Preferred drug delivery applications include the delivery of potent compounds, including both small and large molecules, such as hormones, steroids, chemotherapy medications, vaccines, gene delivery vectors, and some strong analgesic agents.
  • The microchips can be implanted into the body of a human or other animal via surgical procedures or injection, or swallowed, and can deliver many different drugs, at varying rates and varying times. In another embodiment, the microchip device includes one or more biosensors (which may be sealed in reservoirs until needed for use) that are capable of detecting and/or measuring signals within the body of a patient. As used herein, the term “biosensor” includes, but is not limited to, sensing devices that transduce the chemical potential of an analyte of interest into an electrical signal, as well as electrodes that measure electrical signals directly or indirectly (e.g., by converting a mechanical or thermal energy into an electrical signal). For example, the biosensor may measure intrinsic electrical signals (EKG, EEG, or other neural signals), pressure, temperature, pH, or loads on tissue structures at various in vivo locations. The electrical signal from the biosensor can then be measured, for example by a microprocessor/controller, which then can transmit the information to a remote controller, another local controller, or both. For example, the system can be used to relay or record information on the patient's vital signs or the implant environment, such as blood gases, drug concentration, or temperature.
  • The system also has a variety uses that are not limited to implantation. For example, the reservoir contents may include a sensor for detecting a chemical or biological molecule at the site in which the microchip is placed, and the telemetry system transmits a status of the sensor detection to the remote controller. Such a site could be in vivo or in vitro. The chemical or biological molecule could, for example, be associated with a chemical or biological weapon, and the system used in an early warning/detection system.
  • Active microchip devices may be controlled by local microprocessors or remote control. Biosensor information may provide input to the controller to determine the time and type of activation automatically, with human intervention, or a combination thereof. The microchip devices have numerous in vivo, in vitro, and commercial diagnostic applications. The microchips are capable of delivering precisely metered quantities of molecules and thus are useful for in vitro applications, such as analytical chemistry and medical diagnostics, as well as biological applications such as the delivery of factors to cell cultures.
  • Publications cited herein and the materials for which they are cited are specifically incorporated by reference. Modifications and variations of the methods and devices described herein will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the appended claims.

Claims (22)

  1. 1. A device for the controlled release or exposure of molecules or secondary devices comprising:
    a substrate;
    a plurality of reservoirs located in the substrate;
    reservoir contents isolated inside the reservoirs, wherein the reservoir contents are selected from the group consisting of molecules, secondary devices, and combinations thereof;
    reservoir caps positioned on the reservoirs over the reservoir contents, wherein the reservoir caps are mechanically reinforced with a second material deposited and patterned on the surface of the reservoir caps inside the reservoir, on the surface of the reservoir caps outside the reservoir, or on both of said surfaces; and
    control circuitry and a power source for disintegrating the reservoir caps to initiate exposure or release of the reservoir contents in selected reservoirs.
  2. 2. The device of claim 1, wherein the reservoir cap comprises a metal film.
  3. 3. The device of claim 1, wherein the second material is electrically conductive and patterned onto the surface of the reservoir cap outside the reservoir.
  4. 4. The device of claim 1, wherein the second material is electrically nonconductive and patterned onto the surface of the reservoir cap outside the reservoir.
  5. 5. The device of claim 1, wherein the second material is electrically conductive and patterned onto the surface of the reservoir cap inside the reservoir.
  6. 6. The device of claim 1, wherein the second material is electrically nonconductive and patterned onto the surface of the reservoir cap inside the reservoir.
  7. 7. The device of claim 1, wherein the second material comprises oxides or nitrides of silicon, titanium, or chromium.
  8. 8. The device of claim 1, wherein the second material comprises carbides, diamond-like materials, photopolymers, or fluoropolymers.
  9. 9. The device of claim 1, wherein the reservoir contents comprise a therapeutic or prophylactic agent.
  10. 10. The device of claim 1, wherein the reservoir contents comprise molecules selected from the group consisting of enzymes, zeolites, proteins, nucleic acids, polysaccharides, polymers, and cells.
  11. 11. The device of claim 1, wherein the reservoir contents comprises a sensor or sensing component.
  12. 12. The device of claim 1, wherein the reservoir contents comprises a biosensor.
  13. 13. The device of claim 1, wherein the reservoir contents comprises a glucose sensor.
  14. 14. The device of claim 1, further comprising a microprocessor.
  15. 15. The device of claim 14, further comprising a source of memory, a timer, a demultiplexer.
  16. 16. The device of claim 1, which is packaged in a biocompatible material.
  17. 17. The device of claim 16, wherein the biocompatible material is selected from the group consisting of poly(ethylene glycol)s, polytetrafluoroethylenes, and titanium.
  18. 18. A device for the controlled release or exposure of molecules or secondary devices comprising:
    a substrate;
    a plurality of reservoirs located in the substrate;
    reservoir contents isolated inside the reservoirs, wherein the reservoir contents are selected from the group consisting of drug molecules, sensors, and combinations thereof;
    reservoir caps positioned on the reservoirs over the reservoir contents, the reservoir caps comprising a metal film mechanically reinforced with a second material deposited and patterned on the surface of the metal film inside the reservoir, on the surface of the metal film outside the reservoir, or on both of said surfaces; and
    control circuitry and a power source for disintegrating the reservoir caps to initiate exposure or release of the reservoir contents in selected reservoirs.
  19. 19. A method of releasing or exposing reservoir contents in vivo comprising the steps of:
    implanting the device of claim 1 into a patient; and
    disintegrating the reservoir cap of at least one reservoir to open the selected reservoir and release or expose the reservoir contents therein.
  20. 20. The method of claim 19, wherein disintegration of the reservoir cap is controlled by a preprogrammed microprocessor, by remote control, by a signal from a biosensor, or by a combination thereof.
  21. 21. A method of releasing or exposing reservoir contents in vivo comprising the steps of:
    implanting the device of claim 18 into a patient; and
    disintegrating the reservoir cap of at least one reservoir to open the selected reservoir and release or expose the reservoir contents therein.
  22. 22. The method of claim 21, wherein disintegration of the reservoir cap is controlled by a preprogrammed microprocessor, by remote control, by a signal from a biosensor, or by a combination thereof.
US10937616 2001-05-31 2004-09-09 Device for controlled reservoir opening with reinforced reservoir caps Abandoned US20050143715A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US29481801 true 2001-05-31 2001-05-31
US10159550 US6875208B2 (en) 2001-05-31 2002-05-31 Microchip devices with improved reservoir opening
US10937616 US20050143715A1 (en) 2001-05-31 2004-09-09 Device for controlled reservoir opening with reinforced reservoir caps

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10937616 US20050143715A1 (en) 2001-05-31 2004-09-09 Device for controlled reservoir opening with reinforced reservoir caps

Publications (1)

Publication Number Publication Date
US20050143715A1 true true US20050143715A1 (en) 2005-06-30

Family

ID=23135061

Family Applications (2)

Application Number Title Priority Date Filing Date
US10159550 Expired - Fee Related US6875208B2 (en) 2001-05-31 2002-05-31 Microchip devices with improved reservoir opening
US10937616 Abandoned US20050143715A1 (en) 2001-05-31 2004-09-09 Device for controlled reservoir opening with reinforced reservoir caps

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10159550 Expired - Fee Related US6875208B2 (en) 2001-05-31 2002-05-31 Microchip devices with improved reservoir opening

Country Status (2)

Country Link
US (2) US6875208B2 (en)
WO (1) WO2002099457A3 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220531A1 (en) * 2003-05-01 2004-11-04 Bui Tuan S. System and method operating microreservoirs delivering medication in coordination with a pump delivering diluent
US20050055014A1 (en) * 2003-08-04 2005-03-10 Coppeta Jonathan R. Methods for accelerated release of material from a reservoir device
US20060024358A1 (en) * 2004-07-30 2006-02-02 Santini John T Jr Multi-reservoir device for transdermal drug delivery and sensing
US20060057737A1 (en) * 2004-09-01 2006-03-16 Santini John T Jr Multi-cap reservoir devices for controlled release or exposure of reservoir contents
US20060093646A1 (en) * 2004-10-28 2006-05-04 Cima Michael J Orthopedic and dental implant devices providing controlled drug delivery
US20060171989A1 (en) * 2005-01-25 2006-08-03 Prescott James H Control of drug release by transient modification of local microenvironments
US20070016163A1 (en) * 2005-06-28 2007-01-18 Microchips, Inc. Medical and dental implant devices for controlled drug delivery
US20080015494A1 (en) * 2006-07-11 2008-01-17 Microchips, Inc. Multi-reservoir pump device for dialysis, biosensing, or delivery of substances
US20100167128A1 (en) * 2008-12-29 2010-07-01 Taiwan Textile Research Institute Tin/Lithium Oxide Composite Thin Film, Its Preparation and Uses Thereof
US20110196293A1 (en) * 2008-10-10 2011-08-11 Milux Holding Sa Stimulation of penis erection
US20110196294A1 (en) * 2008-10-10 2011-08-11 Milux Holding S.A. Infusion of drugs
US20110201879A1 (en) * 2008-10-10 2011-08-18 Milux Holding Sa Stimulation of penis erection
US8521273B2 (en) 2008-01-29 2013-08-27 Gilbert H. KLIMAN Drug delivery devices, kits and methods therefor
US20150073491A1 (en) * 2009-08-03 2015-03-12 The Research Foundation For The State University Of New York Electrochemical eradication of microbes on surfaces of objects

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070590B1 (en) 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US6872187B1 (en) 1998-09-01 2005-03-29 Izex Technologies, Inc. Orthoses for joint rehabilitation
US9107605B2 (en) * 2000-11-17 2015-08-18 Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. Device for in vivo delivery of bioactive agents and method of manufacture thereof
US7416537B1 (en) * 1999-06-23 2008-08-26 Izex Technologies, Inc. Rehabilitative orthoses
DE60018582T2 (en) * 1999-08-18 2006-01-19 Microchips, Inc., Bedford Thermally activated microchip as a delivery device for chemicals
US6808522B2 (en) * 1999-12-10 2004-10-26 Massachusetts Institute Of Technology Microchip devices for delivery of molecules and methods of fabrication thereof
CA2399842C (en) * 2000-03-02 2006-11-14 Microchips, Inc. Microfabricated devices for the storage and selective exposure of chemicals and devices
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
DE60219607T2 (en) 2001-01-09 2007-12-27 Microchips, Inc., Bedford Flexible micro chip devices for ophthalmic and other application
US8372139B2 (en) 2001-02-14 2013-02-12 Advanced Bio Prosthetic Surfaces, Ltd. In vivo sensor and method of making same
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7316700B2 (en) 2001-06-12 2008-01-08 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
EP1404235A4 (en) 2001-06-12 2008-08-20 Pelikan Technologies Inc Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
WO2002100460A3 (en) 2001-06-12 2003-05-08 Don Alden Electric lancet actuator
WO2003048665A1 (en) 2001-12-03 2003-06-12 Massachusetts Institute Of Technology Microscale lyophilization and drying methods for the stabilization of molecules
US6878909B2 (en) * 2002-03-01 2005-04-12 Board Of Control Of Michigan Technological University Induction heating of thin films
US7193193B2 (en) * 2002-03-01 2007-03-20 Board Of Control Of Michigan Technological University Magnetic annealing of ferromagnetic thin films using induction heating
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US6953455B2 (en) * 2002-07-30 2005-10-11 Hospira, Inc. Medicine delivery system
JP4436258B2 (en) * 2002-08-16 2010-03-24 マイクロチップス・インコーポレーテッド Controlled release devices and methods
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US7534241B2 (en) * 2002-09-23 2009-05-19 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
DE60331455D1 (en) 2002-10-04 2010-04-08 Microchips Inc A heart monitoring medical device for controlled drug delivery, as well as and / or cardiac stimulation
EP1551499A1 (en) * 2002-10-04 2005-07-13 Microchips, Inc. Medical device for neural stimulation and controlled drug delivery
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
DE602004031011D1 (en) * 2003-04-25 2011-02-24 Boston Scient Scimed Inc Solid pharmaceutical formulation and device for its retention and controlled delivery
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US20070036835A1 (en) * 2004-07-19 2007-02-15 Microchips, Inc. Hermetically Sealed Devices for Controlled Release or Exposure of Reservoir Contents
US7114312B2 (en) * 2003-07-17 2006-10-03 Microchips, Inc. Low temperature methods for hermetically sealing reservoir devices
US7612443B1 (en) * 2003-09-04 2009-11-03 University Of Notre Dame Du Lac Inter-chip communication
WO2005033659A3 (en) 2003-09-29 2007-01-18 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
WO2005037095A1 (en) 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
US8095197B2 (en) 2003-11-03 2012-01-10 Microchips, Inc. Medical device for sensing glucose
DE20317944U1 (en) * 2003-11-18 2004-03-11 Heiser, Volker, Dr. Sample carriers for molecules
WO2005065414A3 (en) 2003-12-31 2005-12-29 Pelikan Technologies Inc Method and apparatus for improving fluidic flow and sample capture
US7850676B2 (en) * 2004-04-19 2010-12-14 The Invention Science Fund I, Llc System with a reservoir for perfusion management
US8353896B2 (en) 2004-04-19 2013-01-15 The Invention Science Fund I, Llc Controllable release nasal system
US8337482B2 (en) * 2004-04-19 2012-12-25 The Invention Science Fund I, Llc System for perfusion management
US9801527B2 (en) 2004-04-19 2017-10-31 Gearbox, Llc Lumen-traveling biological interface device
US9011329B2 (en) 2004-04-19 2015-04-21 Searete Llc Lumenally-active device
US8361013B2 (en) 2004-04-19 2013-01-29 The Invention Science Fund I, Llc Telescoping perfusion management system
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH &amp; Co. KG Printable hydrogel for biosensors
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US20060034029A1 (en) * 2004-08-13 2006-02-16 Cyntec Company Current detector with improved resistance adjustable range and heat dissipation
EP1861333A2 (en) * 2004-11-04 2007-12-05 Microchips, Inc. Compression and cold weld sealing methods and devices
US7413846B2 (en) 2004-11-15 2008-08-19 Microchips, Inc. Fabrication methods and structures for micro-reservoir devices
EP1819278A4 (en) * 2004-11-15 2009-04-08 Izex Technologies Inc Instrumented orthopedic and other medical implants
US8308794B2 (en) 2004-11-15 2012-11-13 IZEK Technologies, Inc. Instrumented implantable stents, vascular grafts and other medical devices
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US9022980B2 (en) 2005-02-01 2015-05-05 Kaleo, Inc. Medical injector simulation device
US8206360B2 (en) 2005-02-01 2012-06-26 Intelliject, Inc. Devices, systems and methods for medicament delivery
EP1843812A4 (en) 2005-02-01 2008-12-03 Intelliject Llc Devices, systems, and methods for medicament delivery
US8361026B2 (en) 2005-02-01 2013-01-29 Intelliject, Inc. Apparatus and methods for self-administration of vaccines and other medicaments
US7731686B2 (en) * 2005-02-01 2010-06-08 Intelliject, Inc. Devices, systems and methods for medicament delivery
US8226610B2 (en) 2005-02-01 2012-07-24 Intelliject, Inc. Medical injector with compliance tracking and monitoring
US8231573B2 (en) 2005-02-01 2012-07-31 Intelliject, Inc. Medicament delivery device having an electronic circuit system
JP5265359B2 (en) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー Intravesical drug delivery device and method
US20070088442A1 (en) * 2005-10-14 2007-04-19 Microchips, Inc. Passive wear-indicating sensor for implantable prosthetic device
US7963945B2 (en) * 2005-12-14 2011-06-21 Hewlett-Packard Development Company, L.P. Replaceable supplies for IV fluid delivery systems
WO2007120640A3 (en) * 2006-04-11 2008-10-23 Univ South Florida Thermally induced single-use valves and method of use
CN101460213A (en) * 2006-06-02 2009-06-17 皇家飞利浦电子股份有限公司 Device for the controlled release of a substance
WO2007148238A1 (en) * 2006-06-20 2007-12-27 Koninklijke Philips Electronics, N.V. Electronic capsule for treating gastrointestinal disease
US20090076591A1 (en) * 2007-09-19 2009-03-19 Boston Scientific Scimed, Inc. Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface
US7833266B2 (en) 2007-11-28 2010-11-16 Boston Scientific Scimed, Inc. Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
EP2249893A2 (en) * 2008-02-01 2010-11-17 Boston Scientific Scimed, Inc. Drug-coated medical devices for differential drug release
EP2259714A1 (en) * 2008-02-22 2010-12-15 Herbert Michael Pinedo Device for detecting a medical condition or disease
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
DE102008040253A1 (en) * 2008-07-08 2010-01-14 Biotronik Vi Patent Ag Implant system with a function of degradable implant metal material
US7951193B2 (en) 2008-07-23 2011-05-31 Boston Scientific Scimed, Inc. Drug-eluting stent
US8236238B2 (en) * 2009-01-21 2012-08-07 Palo Alto Research Center Incorporated Drug deactivation system
US7838715B2 (en) * 2009-01-21 2010-11-23 Palo Alto Research Center Incorporated Drug deactivation system and method of deactivating a drug using the same
US9480795B2 (en) * 2009-01-21 2016-11-01 Palo Alto Research Center Incorporated Sensor system for drug delivery device, drug delivery device having the same and method of using the same
US8126736B2 (en) 2009-01-23 2012-02-28 Warsaw Orthopedic, Inc. Methods and systems for diagnosing, treating, or tracking spinal disorders
US8685093B2 (en) 2009-01-23 2014-04-01 Warsaw Orthopedic, Inc. Methods and systems for diagnosing, treating, or tracking spinal disorders
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
FR2945097B1 (en) * 2009-04-30 2011-06-03 Commissariat Energie Atomique microfluidic valve single use.
US8557623B2 (en) * 2009-06-17 2013-10-15 Board Of Regents, The University Of Texas System Methods and apparatuses for integrated packaging of microelectromechanical devices
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US20110059148A1 (en) * 2009-09-07 2011-03-10 National Chiao Tung University Flexible Drug Delivery Chip, its Fabrication Method and Uses Thereof
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US9919103B2 (en) 2012-12-21 2018-03-20 Microchips Biotech, Inc. Implantable medical device for minimally-invasive insertion
WO2014106056A3 (en) 2012-12-27 2015-07-16 Kaleo, Inc. Systems for locating and interacting with medicament delivery devices
US9620473B1 (en) 2013-01-18 2017-04-11 University Of Notre Dame Du Lac Quilt packaging system with interdigitated interconnecting nodules for inter-chip alignment
CN104994901A (en) 2013-02-28 2015-10-21 微芯片生物技术公司 Implantable medical device for minimally-invasive insertion
CN106232066A (en) * 2014-04-25 2016-12-14 庄臣及庄臣视力保护公司 Method and ophthalmic device with active agent release system
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US9937124B2 (en) 2014-09-11 2018-04-10 International Business Machines Corporation Microchip substance delivery devices having low-power electromechanical release mechanisms
US9867932B2 (en) * 2015-10-30 2018-01-16 International Business Machines Corporation Drug delivery device having a cavity sealed by a pressurized membrane
US20170274139A1 (en) * 2016-03-22 2017-09-28 International Business Machines Corporation Secure medication delivery

Citations (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436853B1 (en) *
US3692027A (en) * 1971-04-23 1972-09-19 Everett H Ellinwood Jr Implanted medication dispensing device and method
US4089734A (en) * 1974-09-16 1978-05-16 Raytheon Company Integrated circuit fusing technique
US4146029A (en) * 1974-04-23 1979-03-27 Ellinwood Jr Everett H Self-powered implanted programmable medication system and method
US4209894A (en) * 1978-04-27 1980-07-01 Texas Instruments Incorporated Fusible-link semiconductor memory
US4507115A (en) * 1981-04-01 1985-03-26 Olympus Optical Co., Ltd. Medical capsule device
US4585652A (en) * 1984-11-19 1986-04-29 Regents Of The University Of Minnesota Electrochemical controlled release drug delivery system
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4731051A (en) * 1979-04-27 1988-03-15 The Johns Hopkins University Programmable control means for providing safe and controlled medication infusion
US4731049A (en) * 1987-01-30 1988-03-15 Ionics, Incorporated Cell for electrically controlled transdermal drug delivery
US5041107A (en) * 1989-10-06 1991-08-20 Cardiac Pacemakers, Inc. Electrically controllable, non-occluding, body implantable drug delivery system
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
US5147297A (en) * 1990-05-07 1992-09-15 Alza Corporation Iontophoretic delivery device
US5196002A (en) * 1990-10-09 1993-03-23 University Of Utah Research Foundation Implantable drug delivery system with piston acutation
US5200051A (en) * 1988-11-14 1993-04-06 I-Stat Corporation Wholly microfabricated biosensors and process for the manufacture and use thereof
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5252294A (en) * 1988-06-01 1993-10-12 Messerschmitt-Bolkow-Blohm Gmbh Micromechanical structure
US5304293A (en) * 1992-05-11 1994-04-19 Teknekron Sensor Development Corporation Microsensors for gaseous and vaporous species
US5318557A (en) * 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
US5336213A (en) * 1992-04-08 1994-08-09 International Medical Associates, Inc. Selectable dosage transdermal delivery system
US5380272A (en) * 1993-01-28 1995-01-10 Scientific Innovations Ltd. Transcutaneous drug delivery applicator
US5427585A (en) * 1993-03-29 1995-06-27 Bettinger; David S. On-demand iontophoretic system
US5429822A (en) * 1992-03-13 1995-07-04 Cambridge Scientific, Inc. Biodegradable bursting release system
US5443508A (en) * 1993-03-01 1995-08-22 Giampapa; Vincent C. Subcutaneous implantable multiple agent delivery system
US5493177A (en) * 1990-12-03 1996-02-20 The Regents Of The University Of California Sealed micromachined vacuum and gas filled devices
US5504026A (en) * 1995-04-14 1996-04-02 Analog Devices, Inc. Methods for planarization and encapsulation of micromechanical devices in semiconductor processes
US5510138A (en) * 1994-05-24 1996-04-23 Delco Electronics Corporation Hot melt conformal coating materials
US5533995A (en) * 1991-11-13 1996-07-09 Elan Corporation, Plc Passive transdermal device with controlled drug delivery
US5547470A (en) * 1992-11-25 1996-08-20 Abbott Laboratories Automated drug infusion system
US5605662A (en) * 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5662689A (en) * 1995-09-08 1997-09-02 Medtronic, Inc. Method and apparatus for alleviating cardioversion shock pain
US5770076A (en) * 1994-03-07 1998-06-23 The Regents Of The University Of California Micromachined capsules having porous membranes and bulk supports
US5782799A (en) * 1997-02-07 1998-07-21 Sarcos, Inc. Method for automatic dosing of drugs
US5797898A (en) * 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5824049A (en) * 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5824646A (en) * 1988-03-11 1998-10-20 Teikoku Seiyaku Co., Ltd. Intravaginal delivery of biologically active polypeptides
US5863708A (en) * 1994-11-10 1999-01-26 Sarnoff Corporation Partitioned microelectronic device array
US5869004A (en) * 1997-06-09 1999-02-09 Caliper Technologies Corp. Methods and apparatus for in situ concentration and/or dilution of materials in microfluidic systems
US5872010A (en) * 1995-07-21 1999-02-16 Northeastern University Microscale fluid handling system
US5893974A (en) * 1994-03-07 1999-04-13 Regents Of University Of California Microfabricated capsules for immunological isolation of cell transplants
US5925069A (en) * 1997-11-07 1999-07-20 Sulzer Intermedics Inc. Method for preparing a high definition window in a conformally coated medical device
US5938923A (en) * 1997-04-15 1999-08-17 The Regents Of The University Of California Microfabricated filter and capsule using a substrate sandwich
US5945412A (en) * 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
US5949187A (en) * 1997-07-29 1999-09-07 Motorola, Inc. Organic electroluminescent device with plural microcavities
US5957579A (en) * 1997-10-09 1999-09-28 Caliper Technologies Corp. Microfluidic systems incorporating varied channel dimensions
US6027695A (en) * 1998-04-01 2000-02-22 Dupont Pharmaceuticals Company Apparatus for holding small volumes of liquids
US6051017A (en) * 1996-02-20 2000-04-18 Advanced Bionics Corporation Implantable microstimulator and systems employing the same
US6062461A (en) * 1998-06-03 2000-05-16 Delphi Technologies, Inc. Process for bonding micromachined wafers using solder
US6066163A (en) * 1996-02-02 2000-05-23 John; Michael Sasha Adaptive brain stimulation method and system
US6081736A (en) * 1997-10-20 2000-06-27 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems adapted for long term use
US6096656A (en) * 1999-06-24 2000-08-01 Sandia Corporation Formation of microchannels from low-temperature plasma-deposited silicon oxynitride
US6114658A (en) * 1996-03-15 2000-09-05 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Device for the encapsulated reception of a material
US6178349B1 (en) * 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US6232150B1 (en) * 1998-12-03 2001-05-15 The Regents Of The University Of Michigan Process for making microstructures and microstructures made thereby
US6261584B1 (en) * 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6289237B1 (en) * 1998-12-22 2001-09-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Apparatus for energizing a remote station and related method
US6334859B1 (en) * 1999-07-26 2002-01-01 Zuli Holdings Ltd. Subcutaneous apparatus and subcutaneous method for treating bodily tissues with electricity or medicaments
US20020038137A1 (en) * 1999-04-30 2002-03-28 Medtronic, Inc. Therapeutic treatment of disorders based on timing information
US6376477B2 (en) * 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US6378292B1 (en) * 2000-11-10 2002-04-30 Honeywell International Inc. MEMS microthruster array
US6384353B1 (en) * 2000-02-01 2002-05-07 Motorola, Inc. Micro-electromechanical system device
US20020055761A1 (en) * 1998-07-06 2002-05-09 Mann Carla M. Implantable stimulator systems and methods for treatment of incontinence and pain
US20020072784A1 (en) * 2000-10-10 2002-06-13 Sheppard Norman F. Microchip reservoir devices using wireless transmission of power and data
US20020072734A1 (en) * 2000-12-08 2002-06-13 Pharmed Holding Gmbh Chip systems for the controlled emission of substances having a chemosensory effect
US20020082665A1 (en) * 1999-07-07 2002-06-27 Medtronic, Inc. System and method of communicating between an implantable medical device and a remote computer system or health care provider
US20020099359A1 (en) * 2001-01-09 2002-07-25 Santini John T. Flexible microchip devices for ophthalmic and other applications
US20020107553A1 (en) * 2000-10-26 2002-08-08 Medtronic, Inc. Method and apparatus for electrically stimulating the nervous system to improve ventricular dysfunction, heart failure, and other cardiac conditions
US20020111658A1 (en) * 2001-02-13 2002-08-15 Greenberg Robert J. Implantable retinal electrode array configuration for minimal retinal damage and method of reducing retinal stress
US20020111601A1 (en) * 2001-02-12 2002-08-15 Medtronic, Inc Drug delivery device
US6437640B1 (en) * 2000-09-12 2002-08-20 The Aerospace Corporation Addressable diode isolated thin film array
US20020119176A1 (en) * 2001-02-28 2002-08-29 Greenberg Robert J. Implantable microfluidic delivery system using ultra-nanocrystalline diamond coating
US20030004549A1 (en) * 2000-10-26 2003-01-02 Medtronic, Inc. Method and apparatus to minimize the effects of a cardiac insult
US20030036794A1 (en) * 1995-06-07 2003-02-20 Cook Incorporated Coated implantable medical device
US6527762B1 (en) * 1999-08-18 2003-03-04 Microchips, Inc. Thermally-activated microchip chemical delivery devices
US20030055344A1 (en) * 2000-01-11 2003-03-20 Eigler Neal L. Permanently implantable system and method for detecting diagnosing and treating congestive heart failure
US6537246B1 (en) * 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6537250B1 (en) * 1997-08-27 2003-03-25 Science, Incorporated Fluid delivery device with electrically activated energy source
US20030069560A1 (en) * 2001-05-03 2003-04-10 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US6551838B2 (en) * 2000-03-02 2003-04-22 Microchips, Inc. Microfabricated devices for the storage and selective exposure of chemicals and devices
US6587719B1 (en) * 1999-07-01 2003-07-01 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
US20040043042A1 (en) * 2001-12-03 2004-03-04 Johnson Audrey M. Microscale lyophilization and drying methods for the stabilization of molecules
US20040082937A1 (en) * 2002-09-04 2004-04-29 Dennis Ausiello Method and device for the controlled delivery of parathyroid hormone
US6730072B2 (en) * 2000-05-30 2004-05-04 Massachusetts Institute Of Technology Methods and devices for sealing microchip reservoir devices
US6733485B1 (en) * 2001-05-25 2004-05-11 Advanced Bionics Corporation Microstimulator-based electrochemotherapy methods and systems
US20040106953A1 (en) * 2002-10-04 2004-06-03 Yomtov Barry M. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
US20040106914A1 (en) * 2002-09-23 2004-06-03 Coppeta Jonathan R. Micro-reservoir osmotic release systems and microtube array device
US6757560B1 (en) * 1999-04-09 2004-06-29 Novosis Pharma Ag Transdermal delivery system (TDS) with electrode network
US6773429B2 (en) * 2000-10-11 2004-08-10 Microchips, Inc. Microchip reservoir devices and facilitated corrosion of electrodes
US20040166140A1 (en) * 1996-07-02 2004-08-26 Santini John T. Implantable device for controlled release of drug
US20050100937A1 (en) * 2003-09-11 2005-05-12 Holmes Elizabeth A. Medical device for analyte monitoring and drug delivery
US6908770B1 (en) * 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US7010345B2 (en) * 2000-10-26 2006-03-07 Medtronic, Inc. Method and apparatus to minimize effects of a cardiac insult

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798141A (en) 1972-10-19 1974-03-19 Bell Telephone Labor Inc Technique for electroetching thin film metallization
US4345981A (en) 1978-11-24 1982-08-24 Diamond Shamrock Corporation Anodically polarized surface for biofouling and scale control
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
GB8422876D0 (en) 1984-09-11 1984-10-17 Secr Defence Silicon implant devices
US4994023A (en) 1989-08-08 1991-02-19 Wellinghoff Stephen T Electrochemical drug release and article
EP0538334A1 (en) 1990-07-12 1993-04-28 SEMILAB Félvezeto Fizikai Laboratorium Részvénytarsasag Process for electrochemical dissolution of semiconductors
US5167625A (en) 1990-10-09 1992-12-01 Sarcos Group Multiple vesicle implantable drug delivery system
US5524338A (en) 1991-10-22 1996-06-11 Pi Medical Corporation Method of making implantable microelectrode
US5193539A (en) 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Implantable microstimulator
US5368588A (en) 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5366454A (en) 1993-03-17 1994-11-22 La Corporation De L'ecole Polytechnique Implantable medication dispensing device
US5368704A (en) 1993-08-06 1994-11-29 Teknekron Corporation Micro-electrochemical valves and method
US5824787A (en) 1993-12-03 1998-10-20 Gensura Laboratories, Inc. Polynucleotide sizing reagent
US5985328A (en) 1994-03-07 1999-11-16 Regents Of The University Of California Micromachined porous membranes with bulk support
US5992769A (en) 1995-06-09 1999-11-30 The Regents Of The University Of Michigan Microchannel system for fluid delivery
JPH11508347A (en) 1995-06-21 1999-07-21 フアーマシア・バイオテツク・アー・ベー Method of manufacturing a microstructure comprising a membrane
US5824204A (en) 1996-06-27 1998-10-20 Ic Sensors, Inc. Micromachined capillary electrophoresis device
US6136212A (en) 1996-08-12 2000-10-24 The Regents Of The University Of Michigan Polymer-based micromachining for microfluidic devices
DE19716683C1 (en) 1997-04-21 1998-06-04 Fraunhofer Ges Forschung Miniature encapsulation device for sensitive materials
US6140740A (en) 1997-12-30 2000-10-31 Remon Medical Technologies, Ltd. Piezoelectric transducer
US6171850B1 (en) 1999-03-08 2001-01-09 Caliper Technologies Corp. Integrated devices and systems for performing temperature controlled reactions and analyses
ES2332869T3 (en) 1999-11-17 2010-02-15 Boston Scientific Limited microfabricated devices for delivery of molecules in carrier fluids.
US6808522B2 (en) 1999-12-10 2004-10-26 Massachusetts Institute Of Technology Microchip devices for delivery of molecules and methods of fabrication thereof

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436853B1 (en) *
US3692027A (en) * 1971-04-23 1972-09-19 Everett H Ellinwood Jr Implanted medication dispensing device and method
US4146029A (en) * 1974-04-23 1979-03-27 Ellinwood Jr Everett H Self-powered implanted programmable medication system and method
US4089734A (en) * 1974-09-16 1978-05-16 Raytheon Company Integrated circuit fusing technique
US4209894A (en) * 1978-04-27 1980-07-01 Texas Instruments Incorporated Fusible-link semiconductor memory
US4731051A (en) * 1979-04-27 1988-03-15 The Johns Hopkins University Programmable control means for providing safe and controlled medication infusion
US4507115A (en) * 1981-04-01 1985-03-26 Olympus Optical Co., Ltd. Medical capsule device
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4585652A (en) * 1984-11-19 1986-04-29 Regents Of The University Of Minnesota Electrochemical controlled release drug delivery system
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
US4731049A (en) * 1987-01-30 1988-03-15 Ionics, Incorporated Cell for electrically controlled transdermal drug delivery
US5824646A (en) * 1988-03-11 1998-10-20 Teikoku Seiyaku Co., Ltd. Intravaginal delivery of biologically active polypeptides
US5252294A (en) * 1988-06-01 1993-10-12 Messerschmitt-Bolkow-Blohm Gmbh Micromechanical structure
US5200051A (en) * 1988-11-14 1993-04-06 I-Stat Corporation Wholly microfabricated biosensors and process for the manufacture and use thereof
US5041107A (en) * 1989-10-06 1991-08-20 Cardiac Pacemakers, Inc. Electrically controllable, non-occluding, body implantable drug delivery system
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5147297A (en) * 1990-05-07 1992-09-15 Alza Corporation Iontophoretic delivery device
US5196002A (en) * 1990-10-09 1993-03-23 University Of Utah Research Foundation Implantable drug delivery system with piston acutation
US5493177A (en) * 1990-12-03 1996-02-20 The Regents Of The University Of California Sealed micromachined vacuum and gas filled devices
US5533995A (en) * 1991-11-13 1996-07-09 Elan Corporation, Plc Passive transdermal device with controlled drug delivery
US5429822A (en) * 1992-03-13 1995-07-04 Cambridge Scientific, Inc. Biodegradable bursting release system
US5336213A (en) * 1992-04-08 1994-08-09 International Medical Associates, Inc. Selectable dosage transdermal delivery system
US5304293A (en) * 1992-05-11 1994-04-19 Teknekron Sensor Development Corporation Microsensors for gaseous and vaporous species
US5318557A (en) * 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
US5547470A (en) * 1992-11-25 1996-08-20 Abbott Laboratories Automated drug infusion system
US5380272A (en) * 1993-01-28 1995-01-10 Scientific Innovations Ltd. Transcutaneous drug delivery applicator
US5443508A (en) * 1993-03-01 1995-08-22 Giampapa; Vincent C. Subcutaneous implantable multiple agent delivery system
US5427585A (en) * 1993-03-29 1995-06-27 Bettinger; David S. On-demand iontophoretic system
US5605662A (en) * 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5770076A (en) * 1994-03-07 1998-06-23 The Regents Of The University Of California Micromachined capsules having porous membranes and bulk supports
US5893974A (en) * 1994-03-07 1999-04-13 Regents Of University Of California Microfabricated capsules for immunological isolation of cell transplants
US5510138A (en) * 1994-05-24 1996-04-23 Delco Electronics Corporation Hot melt conformal coating materials
US5863708A (en) * 1994-11-10 1999-01-26 Sarnoff Corporation Partitioned microelectronic device array
US5504026A (en) * 1995-04-14 1996-04-02 Analog Devices, Inc. Methods for planarization and encapsulation of micromechanical devices in semiconductor processes
US20030036794A1 (en) * 1995-06-07 2003-02-20 Cook Incorporated Coated implantable medical device
US5824049A (en) * 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5872010A (en) * 1995-07-21 1999-02-16 Northeastern University Microscale fluid handling system
US5662689A (en) * 1995-09-08 1997-09-02 Medtronic, Inc. Method and apparatus for alleviating cardioversion shock pain
US6261584B1 (en) * 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6066163A (en) * 1996-02-02 2000-05-23 John; Michael Sasha Adaptive brain stimulation method and system
US6051017A (en) * 1996-02-20 2000-04-18 Advanced Bionics Corporation Implantable microstimulator and systems employing the same
US6214032B1 (en) * 1996-02-20 2001-04-10 Advanced Bionics Corporation System for implanting a microstimulator
US6185455B1 (en) * 1996-02-20 2001-02-06 Advanced Bionics Corporation Method of reducing the incidence of medical complications using implantable microstimulators
US6114658A (en) * 1996-03-15 2000-09-05 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Device for the encapsulated reception of a material
US20040166140A1 (en) * 1996-07-02 2004-08-26 Santini John T. Implantable device for controlled release of drug
US6123861A (en) * 1996-07-02 2000-09-26 Massachusetts Institute Of Technology Fabrication of microchip drug delivery devices
US5797898A (en) * 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US6376477B2 (en) * 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US5945412A (en) * 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
US5782799A (en) * 1997-02-07 1998-07-21 Sarcos, Inc. Method for automatic dosing of drugs
US5938923A (en) * 1997-04-15 1999-08-17 The Regents Of The University Of California Microfabricated filter and capsule using a substrate sandwich
US5869004A (en) * 1997-06-09 1999-02-09 Caliper Technologies Corp. Methods and apparatus for in situ concentration and/or dilution of materials in microfluidic systems
US6537246B1 (en) * 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US5949187A (en) * 1997-07-29 1999-09-07 Motorola, Inc. Organic electroluminescent device with plural microcavities
US6537250B1 (en) * 1997-08-27 2003-03-25 Science, Incorporated Fluid delivery device with electrically activated energy source
US5957579A (en) * 1997-10-09 1999-09-28 Caliper Technologies Corp. Microfluidic systems incorporating varied channel dimensions
US6081736A (en) * 1997-10-20 2000-06-27 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems adapted for long term use
US5925069A (en) * 1997-11-07 1999-07-20 Sulzer Intermedics Inc. Method for preparing a high definition window in a conformally coated medical device
US6027695A (en) * 1998-04-01 2000-02-22 Dupont Pharmaceuticals Company Apparatus for holding small volumes of liquids
US6062461A (en) * 1998-06-03 2000-05-16 Delphi Technologies, Inc. Process for bonding micromachined wafers using solder
US20020055761A1 (en) * 1998-07-06 2002-05-09 Mann Carla M. Implantable stimulator systems and methods for treatment of incontinence and pain
US6908770B1 (en) * 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US6232150B1 (en) * 1998-12-03 2001-05-15 The Regents Of The University Of Michigan Process for making microstructures and microstructures made thereby
US6436853B2 (en) * 1998-12-03 2002-08-20 University Of Michigan Microstructures
US6289237B1 (en) * 1998-12-22 2001-09-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Apparatus for energizing a remote station and related method
US6757560B1 (en) * 1999-04-09 2004-06-29 Novosis Pharma Ag Transdermal delivery system (TDS) with electrode network
US6178349B1 (en) * 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US20020038137A1 (en) * 1999-04-30 2002-03-28 Medtronic, Inc. Therapeutic treatment of disorders based on timing information
US6096656A (en) * 1999-06-24 2000-08-01 Sandia Corporation Formation of microchannels from low-temperature plasma-deposited silicon oxynitride
US6587719B1 (en) * 1999-07-01 2003-07-01 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
US20020082665A1 (en) * 1999-07-07 2002-06-27 Medtronic, Inc. System and method of communicating between an implantable medical device and a remote computer system or health care provider
US6334859B1 (en) * 1999-07-26 2002-01-01 Zuli Holdings Ltd. Subcutaneous apparatus and subcutaneous method for treating bodily tissues with electricity or medicaments
US6527762B1 (en) * 1999-08-18 2003-03-04 Microchips, Inc. Thermally-activated microchip chemical delivery devices
US20030105455A1 (en) * 1999-08-18 2003-06-05 Santini John T. Thermally-activated microchip chemical delivery devices
US20030055344A1 (en) * 2000-01-11 2003-03-20 Eigler Neal L. Permanently implantable system and method for detecting diagnosing and treating congestive heart failure
US20030055345A1 (en) * 2000-01-11 2003-03-20 Eigler Neal L. Permanently implantable system and method for detecting, diagnosing and treating congestive heart failure
US6384353B1 (en) * 2000-02-01 2002-05-07 Motorola, Inc. Micro-electromechanical system device
US6551838B2 (en) * 2000-03-02 2003-04-22 Microchips, Inc. Microfabricated devices for the storage and selective exposure of chemicals and devices
US20030104590A1 (en) * 2000-03-02 2003-06-05 Santini, John T. Microfabricated devices for the storage and selective exposure of chemicals and devices
US6730072B2 (en) * 2000-05-30 2004-05-04 Massachusetts Institute Of Technology Methods and devices for sealing microchip reservoir devices
US6437640B1 (en) * 2000-09-12 2002-08-20 The Aerospace Corporation Addressable diode isolated thin film array
US20020072784A1 (en) * 2000-10-10 2002-06-13 Sheppard Norman F. Microchip reservoir devices using wireless transmission of power and data
US6773429B2 (en) * 2000-10-11 2004-08-10 Microchips, Inc. Microchip reservoir devices and facilitated corrosion of electrodes
US20030004549A1 (en) * 2000-10-26 2003-01-02 Medtronic, Inc. Method and apparatus to minimize the effects of a cardiac insult
US20020107553A1 (en) * 2000-10-26 2002-08-08 Medtronic, Inc. Method and apparatus for electrically stimulating the nervous system to improve ventricular dysfunction, heart failure, and other cardiac conditions
US7010345B2 (en) * 2000-10-26 2006-03-07 Medtronic, Inc. Method and apparatus to minimize effects of a cardiac insult
US6378292B1 (en) * 2000-11-10 2002-04-30 Honeywell International Inc. MEMS microthruster array
US20020072734A1 (en) * 2000-12-08 2002-06-13 Pharmed Holding Gmbh Chip systems for the controlled emission of substances having a chemosensory effect
US20020099359A1 (en) * 2001-01-09 2002-07-25 Santini John T. Flexible microchip devices for ophthalmic and other applications
US20020111601A1 (en) * 2001-02-12 2002-08-15 Medtronic, Inc Drug delivery device
US6571125B2 (en) * 2001-02-12 2003-05-27 Medtronic, Inc. Drug delivery device
US20020111658A1 (en) * 2001-02-13 2002-08-15 Greenberg Robert J. Implantable retinal electrode array configuration for minimal retinal damage and method of reducing retinal stress
US20020119176A1 (en) * 2001-02-28 2002-08-29 Greenberg Robert J. Implantable microfluidic delivery system using ultra-nanocrystalline diamond coating
US20030069560A1 (en) * 2001-05-03 2003-04-10 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US6733485B1 (en) * 2001-05-25 2004-05-11 Advanced Bionics Corporation Microstimulator-based electrochemotherapy methods and systems
US20040043042A1 (en) * 2001-12-03 2004-03-04 Johnson Audrey M. Microscale lyophilization and drying methods for the stabilization of molecules
US20040082937A1 (en) * 2002-09-04 2004-04-29 Dennis Ausiello Method and device for the controlled delivery of parathyroid hormone
US20040106914A1 (en) * 2002-09-23 2004-06-03 Coppeta Jonathan R. Micro-reservoir osmotic release systems and microtube array device
US20040106953A1 (en) * 2002-10-04 2004-06-03 Yomtov Barry M. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
US20050100937A1 (en) * 2003-09-11 2005-05-12 Holmes Elizabeth A. Medical device for analyte monitoring and drug delivery

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220531A1 (en) * 2003-05-01 2004-11-04 Bui Tuan S. System and method operating microreservoirs delivering medication in coordination with a pump delivering diluent
US20050055014A1 (en) * 2003-08-04 2005-03-10 Coppeta Jonathan R. Methods for accelerated release of material from a reservoir device
US20060024358A1 (en) * 2004-07-30 2006-02-02 Santini John T Jr Multi-reservoir device for transdermal drug delivery and sensing
US20090234214A1 (en) * 2004-07-30 2009-09-17 Microchips, Inc. Multi-reservoir device and method for transdermal sensing
US20060057737A1 (en) * 2004-09-01 2006-03-16 Santini John T Jr Multi-cap reservoir devices for controlled release or exposure of reservoir contents
US8403915B2 (en) 2004-09-01 2013-03-26 Microchips, Inc. Multi-opening reservoir devices for controlled release or exposure of reservoir contents
US20060093646A1 (en) * 2004-10-28 2006-05-04 Cima Michael J Orthopedic and dental implant devices providing controlled drug delivery
US20060171989A1 (en) * 2005-01-25 2006-08-03 Prescott James H Control of drug release by transient modification of local microenvironments
US20070016163A1 (en) * 2005-06-28 2007-01-18 Microchips, Inc. Medical and dental implant devices for controlled drug delivery
US20080015494A1 (en) * 2006-07-11 2008-01-17 Microchips, Inc. Multi-reservoir pump device for dialysis, biosensing, or delivery of substances
US8521273B2 (en) 2008-01-29 2013-08-27 Gilbert H. KLIMAN Drug delivery devices, kits and methods therefor
US20110196294A1 (en) * 2008-10-10 2011-08-11 Milux Holding S.A. Infusion of drugs
US20110201879A1 (en) * 2008-10-10 2011-08-18 Milux Holding Sa Stimulation of penis erection
US9629722B2 (en) * 2008-10-10 2017-04-25 Peter Forsell Stimulation of penis erection
US9579202B2 (en) * 2008-10-10 2017-02-28 Peter Forsell Infusion of drugs
US20110196293A1 (en) * 2008-10-10 2011-08-11 Milux Holding Sa Stimulation of penis erection
US9750874B2 (en) 2008-10-10 2017-09-05 Peter Forsell Stimulation of penis erection
US8956522B2 (en) * 2008-12-29 2015-02-17 Taiwan Textile Research Institute Tin/lithium oxide composite thin film, its preparation and uses thereof
US20100167128A1 (en) * 2008-12-29 2010-07-01 Taiwan Textile Research Institute Tin/Lithium Oxide Composite Thin Film, Its Preparation and Uses Thereof
US20150073491A1 (en) * 2009-08-03 2015-03-12 The Research Foundation For The State University Of New York Electrochemical eradication of microbes on surfaces of objects
US9616142B2 (en) * 2009-08-03 2017-04-11 The Research Foundation For The State University Of New York Electrochemical eradication of microbes on surfaces of objects

Also Published As

Publication number Publication date Type
WO2002099457A2 (en) application
WO2002099457A8 (en) 2003-01-09 application
US6875208B2 (en) 2005-04-05 grant
WO2002099457A1 (en) 2002-12-12 application
US20020183721A1 (en) 2002-12-05 application
WO2002099457A3 (en) 2003-03-27 application

Similar Documents

Publication Publication Date Title
US6767341B2 (en) Microneedles for minimally invasive drug delivery
US7344499B1 (en) Microneedle device for extraction and sensing of bodily fluids
US6409698B1 (en) Perforate electrodiffusion pump
US20040127942A1 (en) Medical device for neural stimulation and controlled drug delivery
US20050203613A1 (en) Drug delivery stent
US20100069717A1 (en) In-Body Power Source Having High Surface Area Electrode
US20020119176A1 (en) Implantable microfluidic delivery system using ultra-nanocrystalline diamond coating
US20030114366A1 (en) Microfabricated particles and method for treating solid tumors
EP0259536A2 (en) Biological implant with textured surface
US7887508B2 (en) MEMS device and method for delivery of therapeutic agents
US6976982B2 (en) Flexible microchip devices for ophthalmic and other applications
US5002572A (en) Biological implant with textured surface
US6663615B1 (en) Dual stage microvalve and method of use
US6929950B2 (en) Microprojectile delivery system and particulate product
US4793825A (en) Active silicon implant devices
US20040158194A1 (en) Oral devices and methods for controlled drug release
US6334856B1 (en) Microneedle devices and methods of manufacture and use thereof
US6558361B1 (en) Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems
US20060282014A1 (en) Flexible polymer microelectrode with fluid delivery capability and methods for making same
WO2005105053A2 (en) Active drug delivery in the gastrointestinal tract
US20020082543A1 (en) Microneedle devices and production thereof
US7563255B2 (en) Implantable drug delivery device and use thereof
US20020138049A1 (en) Microneedle devices and methods of manufacture and use thereof
US7763277B1 (en) Implants for administering substances and methods of producing implants
US20080015494A1 (en) Multi-reservoir pump device for dialysis, biosensing, or delivery of substances

Legal Events

Date Code Title Description
AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:MASSACHUSETTS INSTITUTE OF TECHNOLOGY;REEL/FRAME:021163/0043

Effective date: 20080624